Lead asset stage 01
NDA filed / NDA-BLA stage [CO029, CE010, CV017] Diligence report
Biosplice Therapeutics
Former Samumed decacorn with an NDA-stage OA asset — strategically credible, but current valuation support is stale and under-disclosed
Historically well-funded NDA-stage biotech with real asset credibility, but stale valuation anchors and missing private metrics keep the call at research-more.
Cover facts
Historical private valuation mark 02
12000 USD million (reported Aug 2018; stale) [CV002, CV038] Latest disclosed financing 03
120 USD million (Apr 2021) [CO013, CV003] Total raised reference 04
~778 USD million (tracker reference) [CV005] Largest disclosed regional deal 05
140 USD million (China license headline) [CI003, CV014] Founded 06
2008 [CO002, CO033] Company profile
Biosplice Therapeutics, formerly Samumed, is a San Diego-headquartered private biotech founded in 2008 that develops small-molecule therapeutics targeting alternative RNA splicing and related CLK/DYRK biology. Its value narrative is dominated by lorecivivint, a knee-osteoarthritis program that reached NDA filing in January 2026, alongside earlier ex-US licensing deals with Haisco in China and Samil in Korea. The broader platform still shows oncology and legacy regenerative programs, but public evidence for near-term enterprise value remains heavily concentrated in lorecivivint and in the company’s ability to convert late-stage clinical progress into approval, reimbursement, and commercialization.
- Website
- www.biosplice.com
- Founded
- 2008-01-01
- Founders
- Osman Kibar, PhD
- Founding location
- San Diego, California, USA
- Headquarters
- San Diego, California, USA
- Product
- Small-molecule therapeutics modulating alternative RNA splicing / CLK-DYRK biology, with lorecivivint as the lead osteoarthritis asset at NDA stage and additional oncology and legacy regenerative programs providing lower- confidence optionality.
- Customers
- Rheumatology and osteoarthritis stakeholders first, with ex-US commercialization partners in China and Korea and longer-dated oncology optionality.
- Business model
- Approval-dependent biotech model combining eventual U.S. product commercialization with ex-US licensing, milestones, and potential royalties.
- Stage
- Private late-stage biotech (NDA-stage lead asset)
- Funding status
- Historical 2018 reported $12B mark; disclosed $120M 2021 financing; current valuation, cash, and terms remain privately held.
Executive summary
Top strengths
- Lorecivivint reached NDA filing in January 2026, giving Biosplice a real late-stage asset rather than a purely preclinical platform story.
- Historical financing access was exceptional, including the widely reported 2018 $438M round and the disclosed $120M 2021 financing.
- Haisco and Samil regional licensing deals provide real external willingness-to-pay signals for lorecivivint.
- The broader platform still shows oncology and legacy pipeline optionality that can matter if the lead asset de-risks.
Top risks
- Current valuation support is stale and indirect; reviewed tracker pages do not substitute for a fresh priced round or signed term sheet.
- Public sources do not disclose current cash, burn, runway, preference stack, or option-pool terms, blocking clean entry underwriting.
- Mixed OA evidence, reimbursement uncertainty, and launch-readiness opacity mean NDA filing does not equal commercial de-risking.
- The 2026 retail-raise narrative is weakly supported and should not be used as a capitalization backstop.
Open gaps
- Current post-money valuation, cap-table ownership, liquidation preferences, and board rights are not public.
- Cash on hand, burn, runway, and downside financing plan remain undisclosed.
- Pricing, reimbursement, and market-access assumptions for lorecivivint are still missing.
- Realized partner economics, milestone receipts, and commercialization-readiness evidence are not public.
Contents
01Company Overview
1.1 Identity, stage, and strategic positioning
Biosplice Therapeutics is best described as a private clinical-stage biotech rather than a commercial pharmaceutical company. Public materials consistently anchor the company in San Diego, position it around small-molecule control of CLK/DYRK kinases and alternative RNA splicing, and frame lorecivivint as the program that carries the present enterprise value narrative. Dealroom places the founding in 2008, while current company materials emphasize the present-day Biosplice brand and its goal of producing disease-modifying therapies rather than incremental symptomatic drugs. That framing matters for diligence because the company is not selling approved medicines today: its operating identity still depends on pipeline credibility, regulatory execution, and access to follow-on capital rather than recurring product revenue. The public record also shows that Biosplice still uses a platform story to explain pipeline breadth across osteoarthritis, oncology, neurology, and other degenerative conditions, but the visible external proof is concentrated overwhelmingly in knee osteoarthritis. That concentration should shape how later chapters weigh optionality outside lorecivivint.[CO001, CO002, CO003, CO004, CO029, CO030]
| Metric | Value / status | Date | Confidence | Gap / note |
|---|---|---|---|---|
| Founded | 2008 (third-party tracker) | 2026 public profile | Medium | Need charter docs to confirm original legal entity lineage |
| Headquarters | San Diego, CA | 2026 | Medium | Public record shows one disclosed HQ address |
| Stage | Private clinical-stage biotech | 2026 | Medium | No approved product revenue disclosed |
| Lead asset | Lorecivivint NDA submitted | 2026-01-06 | Medium | Approval still pending |
| Last disclosed equity round | $120M equity financing | 2021-04-15 | Medium | No fresh priced round disclosed publicly after 2021 |
| Public valuation anchor | Legacy $12B-era peak narrative / stale | 2018 reference | Low | No fresh public price discovery event reviewed |
| Revenue run-rate | Not publicly disclosed | 2026 | Low | Requires audited financials or board package |
| Customer count | Not publicly disclosed / pre-commercial | 2026 | Low | Future commercialization counterparties are known; product customers are not |
| Headcount | Not publicly disclosed | 2026 | Low | Careers page has no open roles but does not state workforce |
Combines official statements and trackers; unavailable private metrics remain explicitly undisclosed rather than estimated.
[CO001, CO002, CO004, CO013, CO027, CO034]Identity, capital, clinical proof, partners, and regulatory dependencies all route through lorecivivint.
[CO003, CO004, CO013, CO018, CO020, CO027]Compact operating indicators show strong milestone visibility but weak disclosure on current commercial metrics.
Items mix official facts with range-bound tracker context; absent private-company metrics remain undisclosed rather than estimated.
[CO001, CO005, CO010, CO013, CO016, CO017]1.2 Leadership, founder influence, and governance coverage
Current management and board materials show a small but functionally complete leadership bench. Erich Horsley is the current chief executive officer, Osman Kibar remains founder and executive chairman, Yusuf Yazici leads medical strategy, Phil Wilson holds the CFO role, and Scott Bulcao covers legal. The board page adds investor-linked governance through Finian Tan of Vickers Venture Partners and Stephen Zachary of Sands Capital, plus Ahmed Khizer Khan and Simon Faure. That structure gives Biosplice visible coverage across strategy, medicine, finance, and legal affairs, but the public record also suggests notable key-person dependence. Kibar remains the founder identity attached to the company’s long-running biology thesis, Horsley appears repeatedly on commercial and financing materials, and Yazici is the most visible clinical spokesperson across osteoarthritis data releases. In other words, governance exists, but the public narrative is still concentrated in a small number of named executives and investors rather than a broad disclosed operating bench.[CO005, CO006, CO007, CO008, CO009, CO010]
| Person | Role | Background / coverage | Founder-market fit or functional relevance | Key-person dependency |
|---|---|---|---|---|
| Osman Kibar, PhD | Founder and Executive Chairman | Founder identity and long-term science narrative | Connects original Samumed/Biosplice thesis to current company | High |
| Erich Horsley | Chief Executive Officer | Leads current corporate and commercialization narrative | Central to present operating and financing messaging | High |
| Yusuf Yazici, MD | Chief Medical Officer | Visible clinical spokesperson for lorecivivint | Anchors OA trial interpretation and regulatory framing | High |
| Phil Wilson | Chief Financial Officer | Finance, fundraising, investor communication | Relevant for private financing continuity and future capital planning | Medium |
| Scott W. Bulcao | Chief Legal Officer | Legal and transaction support | Important for licensing, IP, and diligence execution | Medium |
Table covers currently named executives visible on public management surfaces.
[CO005, CO006, CO007, CO008, CO009]| Stakeholder | Role | Control / economic importance | Diligence ask |
|---|---|---|---|
| Osman Kibar | Founder / executive chairman | Scientific and governance influence appears central | Verify current ownership, voting rights, and financing control terms |
| Vickers Venture Partners | Board-linked investor | Visible board representation via Finian Tan | Request round-by-round ownership and protective provisions |
| Sands Capital | Board-linked investor | Visible board representation via Stephen Zachary | Request fund ownership and any information rights |
| Eventide / aMoon | 2021 financing entrants | Signal specialist biotech investor support | Confirm whether they remained active beyond 2021 |
| SymBiosis / Verition / others | Reported round participants | Broadened private investor base in 2021 | Reconcile exact positions with cap table |
| Haisco and Samil | Regional commercial partners | Potential non-dilutive validation and commercialization leverage | Review milestone schedules, royalties, and termination rights |
Map focuses on disclosed investors and regional partners that visibly matter to capital access or commercialization.
[CO010, CO011, CO015, CO018, CO019, CO020]Public chronology from founding through the 2026 NDA filing shows a long and non-linear commercialization path.
[CO002, CO013, CO018, CO019, CO020, CO021]1.3 Capital history, investors, and valuation ambiguity
The clearest disclosed financing event after the 2021 rebrand is the April 2021 $120 million equity financing, which the company tied directly to lorecivivint and a broader alternative-splicing platform agenda. SEC Form D filings in March 2021 and August 2022 corroborate that Biosplice remained in private fundraising mode after the rebrand, but the public filings do not by themselves provide a fresh market-clearing valuation. Instead, valuation context comes from third-party trackers. Dealroom still reflects a 2008-founded San Diego biotech with a legacy decacorn reputation, while Caplight, Seedtable, Tracxn, and private-market trading pages preserve historical funding-round references but do not surface a clean post-2021 repricing event in the public domain. This leaves investors with a stale mark problem: Biosplice still carries the memory of its 2018 $12 billion-era story, but the public evidence set is much stronger on financing chronology than on present fair value. The claimed 2026 retail raise could change that view materially, but in the reviewed source set it remains low-confidence and unconfirmed by official company channels.[CO013, CO014, CO015, CO016, CO017, CO034]
| Event / anchor | Date | Value / status | Evidence class | Implication |
|---|---|---|---|---|
| 2021 equity financing | 2021-04-15 | $120M disclosed | Official + SEC corroboration | Most concrete post-rebrand primary capital event |
| SEC Form D filing | 2021-03-03 | Filed | Primary filing | Supports continuity of private fundraising |
| SEC Form D filing | 2022-08-24 | Filed | Primary filing | Shows follow-on exempt-offering activity |
| Legacy valuation narrative | 2018 peak period | $12B-era tracker anchor | Third-party trackers | Public mark is stale and not refreshed by recent priced round |
| 2026 accredited-share trading profile | 2026 | Secondary-market listing only | Third-party market-data | Suggests interest but not company-approved valuation |
| 2026 retail-raise narrative | 2026 | Unconfirmed / conflicting | Low-confidence news | Requires primary documents before underwriting |
Uses directly disclosed capital events where possible and marks valuation items separately when only trackers or low-confidence market pages support them.
[CO013, CO016, CO017, CO034, CO035, CO039]1.4 Milestones, regional partnerships, and execution signals
The company’s milestone record is mixed rather than linear. On the positive side, Biosplice converted lorecivivint from a long-running osteoarthritis program into a January 2026 NDA filing, signed regional deals with Haisco in China and Samil in Korea, and kept the broader pipeline visible through publications, conference presentations, and oncology trial starts. On the negative side, the public milestone trail also records why investors should not read the NDA as de-risking the story entirely. In 2022 the company acknowledged earlier phase 3 trials that missed primary pain endpoints in all-comers, and in April 2024 it disclosed that OA-21 also missed its 12-week primary endpoint even while OA-07 continued to show a more favorable long-term structure and symptom profile. The resulting chronology is important: Biosplice did not follow a clean successive-hit sequence into approval; it advanced through mixed phase 3 evidence, subgroup interpretation, and regulatory consultation. That makes the 2026 filing a major milestone, but not a sufficient reason to ignore path-dependence and data-interpretation risk.[CO018, CO019, CO020, CO021, CO022, CO023]
| Date | Event | Type | Amount / status | Participants | Implication |
|---|---|---|---|---|---|
| 2008 | Company founded (tracker anchor) | founding | Founded 2008 | Legacy Samumed/Biosplice entity | Sets age and long development arc |
| 2015-09 | Phase 2 OA study begins | product | OA-02 clinical program | Biosplice / ClinicalTrials.gov | Shows long clinical-development duration |
| 2021-04 | Biosplice closes equity financing | financing | $120M | Eventide, aMoon, SymBiosis, Sands, Verition, others | Provides post-rebrand capital support |
| 2021-04 | Korean regional rights licensed | partnership | Commercial rights granted | Samil | Adds ex-US commercialization pathway |
| 2021-09 | China regional rights licensed | partnership | $140M aggregate value | Haisco | Adds non-dilutive partnership economics |
| 2022-11 | Mixed phase 3 data disclosed | adverse | OA-10/OA-11 missed primary endpoints in all-comers | Biosplice | Introduces interpretation risk |
| 2022-11 | OA-21 design advanced after FDA discussion | regulatory | Study planned / enrollment expected | Biosplice + FDA | Shows active regulatory engagement |
| 2023-11 | OA-07 long-term results presented | product | Structure and pain benefit presented | Biosplice / ACR | Improves clinical narrative |
| 2024-04 | OA-21 primary endpoint missed | adverse | Week-12 pain endpoint not met | Biosplice | Keeps approval path non-linear |
| 2026-01-06 | NDA submitted for lorecivivint | regulatory | NDA filed | Biosplice + FDA | Largest public milestone to date |
This is the single chronology of record for publicly visible company milestones relevant to later chapters.
[CO002, CO013, CO018, CO019, CO020, CO021]Biosplice's public chronology contains both de-risking milestones and material execution setbacks.
Counts are based only on milestones reviewed in this chapter and are directional rather than exhaustive across the company's full history.
[CO013, CO018, CO020, CO021, CO026, CO027]1.5 What the overview settles and what remains unresolved
The overview chapter can settle identity, headquarters, named leadership, visible board composition, disclosed 2021 financing, regional licensing milestones, and the fact pattern behind the 2026 NDA submission. It cannot settle current revenue, headcount, cap-table detail, debt exposure, or whether a very large 2026 retail financing actually closed. Public materials also leave the non-lorecivivint pipeline more weakly substantiated than the company’s headline platform narrative suggests. For diligence purposes, that means later chapters should reuse the overview as ground truth on the company’s public identity and chronology while preserving skepticism on unsupported scale metrics. The right takeaway is not that Biosplice lacks substance; rather, it is that public evidence is strongest on lorecivivint’s regulatory arc and much thinner on private-company operating metrics, present valuation support, and capitalization after 2022. That gap is large enough that any investment decision should demand fresh primary materials rather than lean on legacy unicorn mythology or tracker extrapolations.[CO029, CO030, CO031, CO032, CO038, CO039]
02Market Analysis
2.1 Market boundary and what counts as the opportunity
The addressable market for Biosplice should not be framed as all arthritis spend or even all orthopedic intervention spend. Public evidence supports a narrower definition: knee osteoarthritis patients who cycle through chronic symptom-management pathways and could plausibly receive an intra-articular injection intended to deliver both symptom relief and structural benefit. That excludes rheumatoid-arthritis biologics, broad chronic-pain management spend, unrelated musculoskeletal surgery, and most general orthopedic implants. In practice, lorecivivint enters a care pathway already dominated by exercise, weight management, oral or topical pain therapy, corticosteroid injections, hyaluronic-acid injections, and eventual arthroplasty. The chapter therefore treats the relevant market as the knee-OA treatment pathway in which clinicians, payers, and patients decide whether to escalate from symptom-focused care toward a novel disease-modifying injection. That boundary is strategically narrower than generic OA therapeutics TAMs, but it is the one that matters for adoption and valuation.[CM001, CM002, CM010, CM011, CM017, CM032]
| Segment / category | Included spend or activity | Excluded spend | Buyer / payer | Relevance |
|---|---|---|---|---|
| Knee OA disease-modifying injection opportunity | Specialist-delivered intra-articular therapy for symptomatic knee OA | All arthritis categories and unrelated orthopedic spend | Clinician + payer | Core addressable market for lorecivivint |
| Status-quo conservative care | Exercise, weight management, oral/topical analgesics, PT | Not a direct monetization lane for Biosplice | Patient + payer | Baseline alternative against which adoption is judged |
| Incumbent injection therapies | Corticosteroids and viscosupplements | Curative or structural-regeneration claims | Clinician + payer | Most relevant near-term competitive set |
| Late-stage surgical care | Arthroplasty and hospital surgery | Upstream injection market | Provider + payer | Important substitute, but outside Biosplice's direct product scope |
Boundary focuses on knee-OA treatment decisions rather than generic arthritis market headlines.
[CM001, CM002, CM010, CM011, CM032]Each step from disease burden to reimbursed use removes a large share of the apparent market.
Last step is zero because lorecivivint remained unapproved at the research date.
[CM003, CM004, CM005, CM013, CM023, CM036]2.2 Prevalence-led sizing is more defensible than broad dollar TAM
Public evidence is much better at sizing the osteoarthritis problem in people than in dollars. Biosplice's own OA page cites roughly 51.9 million U.S. adults and 527.8 million adults globally with osteoarthritis, while the 2026 NDA release rounds those figures to roughly 50 million and 500 million-plus. Both sources place U.S. knee osteoarthritis around 25 million adults. The company also argues, using its own trial interpretation, that earlier-stage KL2 and early KL3 patients represent about 70% of the knee-OA population it cares most about. That does not create a realized commercial SAM by itself, but it does offer a more evidence-backed sizing logic than plugging one analyst dollar-TAM into a valuation model. For this report, the safest approach is to treat prevalence, subgroup eligibility, and clinical workflow fit as the primary lenses, while preserving a hard gap on price-based SAM and SOM.[CM003, CM004, CM005, CM006, CM012, CM013]
| Lens | Publisher / method | Geography | Value | Confidence | Limitation |
|---|---|---|---|---|---|
| All OA adults | Biosplice OA page / burden summary | Global | 527.8M adults | Medium | Company cites burden source rather than raw dataset on-page |
| All OA adults | Biosplice NDA release / rounded burden summary | US + Global | ~50M US / 500M+ global | Medium | Rounded company statement |
| Knee OA adults | Biosplice OA page and NDA release | United States | 24.7M to ~25M adults | Medium | Approximate public burden figure |
| Earlier-stage preferred subgroup | Biosplice OA-10/OA-11 interpretation | United States | ~70% of knee OA population | Medium | Subgroup share is company-interpreted rather than epidemiology consensus |
| Illustrative preferred-subgroup population | Report estimate using 25M * 70% | United States | ~17.5M adults | Low | Prevalence lens, not priced SAM or reachable SOM |
Uses prevalence and subgroup lenses instead of unsupported annual-dollar TAM claims.
[CM003, CM004, CM005, CM006, CM013, CM014]Different public lenses agree on a very large OA burden but not on a priced annual revenue market.
Counts are prevalence lenses; they are not annual revenue estimates.
[CM003, CM004, CM005, CM006, CM007, CM013]The decision chain spans patients, specialist injectors, payers, and evidence gatekeepers.
[CM015, CM016, CM025, CM026, CM031, CM033]2.3 Buyer, user, and payer map
The economic and clinical decision chain for lorecivivint is multilayered. The patient bears the disease burden, but the clinician is the operational user who diagnoses stage, decides on injection appropriateness, and performs administration. Health systems and insurers are the economic gatekeepers because guideline placement and reimbursement shape whether a novel injectable therapy becomes standard practice or remains restricted. This matters because Biosplice is not launching a self-administered retail drug; it is pursuing a specialist-delivered procedure-like product that must fit orthopedics, rheumatology, and sports-medicine workflows. The most commercially attractive patients appear to be earlier-stage knee-OA patients who still have enough joint structure to justify a disease-modification argument and who want to delay surgery. But public sources do not yet prove how quickly physicians would adopt a once- or twice-yearly injection or how payers would underwrite a premium versus incumbent symptom-focused injections.[CM015, CM016, CM025, CM026, CM031, CM033]
| Segment | Buyer | User | Payer | Workflow / adoption trigger | Budget owner |
|---|---|---|---|---|---|
| Symptomatic early-stage knee OA patient | Health system / clinic | Orthopedist, rheumatologist, sports medicine physician | Commercial insurer / Medicare / patient cost-share | Needs evidence beyond symptom-only injections | Medical benefit |
| Moderate-to-severe chronic knee OA patient | Health system / clinic | Injecting specialist | Commercial insurer / Medicare | Wants surgery delay or improved function | Medical benefit |
| Regional commercialization partner | Partner pharma company | Local commercial and medical teams | Partner balance sheet | Ex-US launch rights and milestone economics | Partner P&L |
| Guideline / evidence gatekeeper | Professional society / payer body | Clinical and HTA reviewers | Payer or public system | Requires durable efficacy and safety package | Formulary / coverage committee |
Buyer, user, and payer are not the same actor for a novel OA injection.
[CM015, CM016, CM025, CM026, CM031, CM033]Lorecivivint must move through specialist workflow and payer review rather than a simple retail prescription channel.
[CM010, CM011, CM015, CM016, CM017, CM032]2.4 Growth drivers and the adoption constraints that matter most
The demand-side drivers are straightforward: osteoarthritis prevalence is large and rising, the condition produces substantial pain and functional loss, and the market still lacks an approved disease-modifying drug. Those factors create real strategic room for a therapy that can plausibly show more than temporary analgesia. The harder part is conversion from unmet need to reimbursed adoption. Biosplice's own public releases show why. The company can point to long-term structural and symptom data from OA-07, but it also acknowledged missed primary pain endpoints in earlier phase 3 studies and again in OA-21 at 12 weeks. Those misses matter not only for regulation but also for the commercial story, because payers and clinicians need a crisp proof package if a new injection is to displace conservative care and familiar incumbents like corticosteroids or viscosupplements. The market is therefore attractive, but it is also unusually sensitive to endpoint design, subgroup selection, reimbursement proof, and label scope.[CM007, CM008, CM009, CM018, CM019, CM020]
| Driver / constraint | Direction | Timing | Implication | Diligence ask |
|---|---|---|---|---|
| Large and rising OA prevalence | Positive | Long term | Supports durable need for better therapies | Validate targetable subpopulation with management model |
| No approved DMOAD in OA | Positive | Current | Creates whitespace if efficacy is accepted | Test physician and payer appetite for a new category |
| Pain + structure proposition | Positive | Launch dependent | Could differentiate from symptom-only injections | Review label expectations and HEOR package |
| Missed OA-21 primary endpoint | Negative | Current | Raises approval and adoption friction | Review full trial package and subgroup plan |
| Mixed OA-10/OA-11 all-comer results | Negative | Current | Shows endpoint and placebo-response sensitivity | Assess robustness of subgroup thesis |
| Entrenched low-cost conservative care | Negative | Current | Makes premium reimbursement harder | Request pricing and access strategy |
| Incumbent injection therapies | Negative | Current | Sets clinical and economic comparison bar | Build competitor and payer comparison pack |
Rows link clinical evidence directly to market expansion or delay risk.
[CM007, CM008, CM009, CM017, CM018, CM019]2.5 What the market chapter can and cannot settle from public evidence
This chapter can settle market boundary, prevalence order of magnitude, incumbent care pathways, likely buyer-user-payer structure, and the reason the opportunity is interesting despite long development timelines. It cannot settle a clean annual dollar SAM, payer willingness to reimburse a premium disease-modifying OA therapy, or real-world physician adoption curves post-approval. Those are not minor omissions; they are the main variables that convert a clinically credible market into a valuable one. As a result, later financial and valuation chapters should reuse the prevalence-led market logic but avoid false precision on near-term revenue or penetration. The correct diligence posture is to treat the knee-OA market as large, clinically painful, and strategically under-served, while preserving specific asks on pricing, coverage, launch sequencing, and specialty adoption.[CM023, CM024, CM029, CM037, CM038]
03Competitors
3.1 Competitive landscape: incumbents and substitutes matter more than direct DMOAD peers
Biosplice is trying to enter a market that already solves the knee-osteoarthritis job in several different ways, but not with an approved disease-modifying product. The relevant competitor set therefore has to be broader than biotech peers alone. It includes corticosteroid injections such as Zilretta, multiple hyaluronic-acid viscosupplements, conservative care, and the eventual surgical path to arthroplasty. That framing matters because buyers do not need another experimental platform; they need a reason to switch away from familiar pain-relief tools or to use a new therapy earlier in the pathway before surgery. Public evidence also suggests the direct approved-peer field for a DMOAD-style OA claim is still thin, which can help Biosplice if approval lands. But in practice the company will still be judged against the therapies clinicians already know how to inject and payers already know how to cover.[CP001, CP002, CP003, CP004, CP005, CP006]
| Competitor / alternative | Category | Scale / status | Target segment | Differentiation | Limitation |
|---|---|---|---|---|---|
| Lorecivivint | Biosplice candidate | NDA filed, approval pending | Knee OA, especially earlier-stage patients | Disease-modifying thesis plus pain/function story | No approved commercial proof yet |
| Zilretta | Incumbent corticosteroid | Approved commercial product | OA knee pain | Extended-release steroid pain relief | No structural-modification claim |
| Synvisc-One | Incumbent viscosupplement | Approved commercial product | OA knee pain | Single-injection HA brand familiarity | Symptom-relief framing |
| Monovisc / Orthovisc | Incumbent viscosupplements | Approved commercial products | OA knee pain | Convenience or installed-base familiarity | No disease-modification thesis |
| Total knee replacement | Substitute surgery | Entrenched downstream procedure | Severe or refractory OA | Definitive mechanical intervention | Highly invasive and late-pathway |
Direct approved DMOAD peers are thin; practical competition is incumbent symptom management and surgery.
[CP001, CP002, CP003, CP005, CP006, CP016]Biosplice is differentiated on category ambition, while incumbents are stronger on current market readiness.
Axes are ordinal evidence-backed scores, not measured market shares.
[CP001, CP002, CP005, CP007, CP010, CP030]3.2 Biosplice is differentiated on category thesis, not on commercial entrenchment
Lorecivivint is marketed around the idea that it could do more than temporary pain control by affecting structure and function. That is the core reason investors and clinicians would consider it materially different from incumbent steroid and hyaluronic-acid products. The problem is that Biosplice's own public evidence base is mixed. The company can point to OA-07 structure and symptom data, but it also disclosed missed primary pain endpoints in OA-21 and earlier mixed all-comer phase 3 results. That means the product may still be strategically differentiated without yet being commercially dominant. Compared with established incumbents, Biosplice lacks approved-label familiarity, routine office use, and accumulated reimbursement precedent. So the competitive story is not that lorecivivint is already stronger on every axis; it is that it could create a new axis if regulators and payers accept the underlying evidence package.[CP007, CP008, CP009, CP015, CP027, CP031]
| Buying criterion | Lorecivivint | Zilretta | Synvisc-One / HA set | Cingal | Surgery |
|---|---|---|---|---|---|
| Pain relief framing | Yes | Yes | Yes | Yes | Yes |
| Structural-modification thesis | Yes (company-claimed) | No public claim | No public claim | No public claim | Not comparable |
| Approved today | No | Yes | Yes | Varies by market | Yes |
| Specialist office workflow | Planned | Yes | Yes | Yes | No, surgical setting |
| Coverage familiarity | Unknown / pending | Higher | Higher | Unknown | High |
Unsupported cells stay directional or unknown; vendor pages are not independent proof of superiority.
[CP007, CP008, CP010, CP018, CP027, CP029]Incumbents win today on approved workflow fit; lorecivivint wins only on differentiated category thesis.
[CP007, CP010, CP018, CP027, CP032, CP038]3.3 Incumbent distribution, coverage familiarity, and workflow fit are real moats
Commercial power in knee OA does not come only from molecule novelty. It also comes from where a therapy sits in everyday workflow. Products like Monovisc, Orthovisc, Synvisc-One, Zilretta, and Euflexxa are already framed for specialist injection offices, and some have clear distribution or coverage signals that Biosplice does not yet possess. J&J MedTech distribution around Monovisc and Orthovisc, Medicare coverage language on Euflexxa, and Orthovisc's large installed base all point to incumbent channel depth. Even where public net-price evidence is weak, familiarity itself is a moat because it lowers decision friction for clinicians and payers. Biosplice therefore has to win not just a head-to-head science argument, but an access and habit-change argument. That raises switching costs and makes approval only the first step in competition.[CP010, CP011, CP012, CP013, CP014, CP017]
| Product | Dose / package model | Price visibility | Coverage / channel signal | Implication |
|---|---|---|---|---|
| Lorecivivint | Novel injection; final schedule not public in reviewed sources | Unknown | Pending FDA and payer review | Commercial model still speculative |
| Monovisc | Single injection | Weak public price transparency | J&J MedTech distribution signal | Convenience can aid adoption |
| Synvisc-One | Single injection | Weak public price transparency | Entrenched HCP positioning | Familiar office workflow |
| Orthovisc | Three or four weekly injections | Weak public price transparency | Large installed base; J&J-linked US distribution note | More visit burden but high familiarity |
| Euflexxa / Hyalgan | Multi-injection HA regimens | Weak public price transparency | Euflexxa highlights Medicare Part B coverage | Reimbursement familiarity matters |
Public competitor pages rarely expose usable net pricing, so packaging and access signals carry more analytic weight.
[CP011, CP012, CP013, CP017, CP018, CP019]Competitive durability is conditional because Biosplice is strong on thesis but weak on current readiness.
[CP001, CP010, CP023, CP026, CP039]3.4 Portfolio breadth adds optionality, but it can also dilute focus
The company is not purely a knee-OA commercial story. ClinicalTrials.gov and NCI materials show Biosplice continuing to advance oncology programs such as SM04755 and cirtuvivint. That can be interpreted positively as evidence the alternative-splicing platform has applications beyond one asset. It can also be interpreted negatively when capital is scarce, because management focus and cash may need to support multiple programs at once. The terminated SM08502 combination study is a useful reminder that portfolio decisions can change for business reasons, not only scientific ones. For competitor analysis, the main implication is that Biosplice may have more strategic options than a one-asset biotech, but it also faces an internal allocation challenge that mature incumbent injection brands do not. That is not a direct product competitor, but it is a real competitive-readiness variable.[CP022, CP023, CP024, CP025, CP035]
| Moat claim | Threat | Severity | Mitigation / diligence ask |
|---|---|---|---|
| First-mover DMOAD-style category | Label narrower than hoped | High | Review label scenarios and HEOR package |
| Differentiated structure-plus-symptom story | Mixed phase 3 evidence | High | Inspect full trial set and subgroup reproducibility |
| Platform breadth | Management focus split across OA and oncology | Medium | Request capital allocation and launch staffing plan |
| Novelty premium | Incumbent channel and reimbursement familiarity | High | Model access strategy and physician switching |
| Potential IP protection | Weak public IP visibility | Medium | Obtain patent counsel view, do not rely on tracker alone |
Competitive durability is conditional and more commercial than purely scientific at this stage.
[CP008, CP009, CP023, CP024, CP026, CP028]3.5 Moat durability depends on label strength and payer acceptance, not just novelty
If lorecivivint reaches the market, its moat will come from being first into a potentially new disease-modifying OA category, not from already owning distribution. That can be powerful if the label supports a differentiated structure-plus-symptom story. It can evaporate quickly if the label is narrow, uptake is slow, or incumbents adapt with contracting and convenience-focused response. Public data do not yet let this chapter prove strong IP durability, true physician switching shares, or precise price competition. The right conclusion is therefore conditional: Biosplice may have a meaningful thesis moat, but incumbents currently look stronger on trust, reimbursement familiarity, and commercial durability. The most important next diligence asks are full label economics, physician willingness to switch, and how access strategy will offset entrenched workflow behavior.[CP026, CP028, CP029, CP036, CP037, CP039]
04Financials
4.1 Revenue model is still mostly prospective
Public evidence does not show an operating business with recognized product revenue today. Lorecivivint remained unapproved at the research date, which means the most defensible financial framing is still prospective rather than realized. The visible monetization paths are future U.S. product sales if approval lands, ex-US licensing economics with partners such as Haisco and Samil, and downstream milestone or royalty flows that may emerge only if those partnerships progress. That is very different from a business with current recurring revenue or disclosed commercial units. The chapter therefore treats Biosplice as a late-stage biotech whose economic model is approval-contingent. Financial strength, if any, comes from deal optionality and investor willingness to keep funding development rather than from demonstrated commercial cash generation.[CI001, CI002, CI003, CI004, CI005, CI009]
| Stream | Mechanism | Unit | Current status | Quality | Diligence ask |
|---|---|---|---|---|---|
| U.S. product sales | Direct commercialization after approval | Per treated patient / injection | Not yet active | Low current visibility | Request launch model and pricing assumptions |
| China licensing | Upfront + milestones + possible royalties | Contracted partner economics | Publicly announced | Medium headline value, low accounting visibility | Request receipt schedule and royalty terms |
| Korea licensing | Upfront + milestones + possible royalties | Contracted partner economics | Publicly announced | Medium headline value, low accounting visibility | Request receipt schedule and royalty terms |
| Other pipeline partnerships | Future optionality | Unknown | Not publicly quantified | Low | Request BD pipeline and term-sheet status |
Public revenue evidence is dominated by contingent licensing economics rather than recognized sales.
[CI001, CI002, CI003, CI004, CI005, CI025]Public economics flow from approval toward partner milestones and eventual product sales, not current operating revenue.
[CI001, CI002, CI003, CI004, CI009, CI025]4.2 Licensing economics are visible; GTM efficiency is not
The Haisco and Samil announcements are the clearest public monetization evidence because they put explicit aggregate values on regional rights. The Haisco transaction was described as up to $140 million, including $20 million in upfront and early development milestones, while the Samil deal was described as up to $70 million in aggregate value. Those are useful clues about how external partners price the asset. They are not the same as recognized revenue, cash on hand, or repeatable commercial efficiency. The company is still too early for public CAC, payback, or sales-cycle disclosure to be meaningful. As a result, GTM analysis in this chapter focuses on geography, partner structure, and contingent economics instead of software-like efficiency metrics. That is the right level of precision for an NDA-stage biotech with limited public commercialization detail.[CI003, CI004, CI005, CI011, CI012, CI013]
| Price / contract model | List vs realized pricing | Discounts / unknowns | Source |
|---|---|---|---|
| Lorecivivint U.S. launch price | Unknown | All realized economics unknown | NDA press release / OA page |
| Haisco transaction | Up to $140M aggregate, incl. $20M upfront + early development milestones | Royalty and milestone waterfall not disclosed | Company + Fierce + MarketScreener |
| Samil transaction | Up to $70M aggregate value | Receipt timing and accounting not disclosed | Company + BioSpace + KoreaBioMed |
| Secondary-market stock price proxy | Notice price only | Not operating monetization; not audited valuation | Notice |
Headline contract values should not be mistaken for recognized revenue.
[CI003, CI004, CI005, CI018, CI021, CI023]The public record exposes partner deal values but leaves most direct unit-economics inputs unavailable.
[CI010, CI012, CI014, CI015, CI023, CI028]4.3 Cost structure is obvious in shape and opaque in amount
Even without audited statements, the broad cost structure is easy to infer. Biosplice has financed a long clinical program, repeated blinded multicenter studies, regulatory submission work, and whatever pre-launch manufacturing and medical-operations buildout an NDA-stage asset requires. Those are expensive activities. What public sources do not reveal is almost everything an underwriter would want for real modeling: gross margin path, cost of goods, inventory build, launch working capital, monthly burn, or the timing of milestone receipts. This is an important distinction. The chapter can responsibly call Biosplice capital intensive, but it cannot responsibly assign a precise margin profile or runway. That missing granularity should reduce confidence in any near-term financial scenario even if the broader strategic case for the product remains interesting.[CI014, CI015, CI016, CI022, CI023, CI028]
| Metric | Value / null | Confidence | Why it matters | Diligence ask |
|---|---|---|---|---|
| Gross margin | null | Low | Needed to judge biotech launch economics | Request COGS and manufacturing assumptions |
| Cost of goods per injection | null | Low | Determines profitability after approval | Request formulation and fill-finish cost estimates |
| Working capital requirement | null | Low | Launch inventory can absorb cash | Request inventory build and payment terms |
| Customer acquisition cost | null | Low | Commercial field model unknown | Request launch staffing and channel plan |
| Sales cycle / reimbursement cycle | null | Low | Determines speed of ramp | Request payer access and account sequencing plan |
Nulls are deliberate because the public record does not support faux precision.
[CI010, CI011, CI014, CI015, CI023, CI028]Capital intensity is visible even though actual cash-flow figures are not.
[CI014, CI016, CI018, CI019, CI032, CI034]4.4 Capital adequacy remains the main financial unknown
The public record clearly shows that Biosplice has raised private capital repeatedly, including a 2021 equity financing and multiple Form D filings. It also shows that the company used regional licensing to supplement the funding story around lorecivivint. What it does not show is current liquidity. Neither Form D filings nor press releases provide audited cash on hand, monthly burn, runway months, or a live preference stack. The NDA filing may improve financing leverage because regulatory review can compress perceived development risk, but it does not prove that the company is funded through launch. The unverified 2026 retail-raise narrative further complicates the picture because it is material if true but weakly supported in the retained source set. The correct public-data stance is that Biosplice is financing dependent, plausibly better positioned after the NDA, but not demonstrably well capitalized.[CI006, CI007, CI008, CI016, CI017, CI020]
| Item | Public signal | Confidence | Implication | Diligence ask |
|---|---|---|---|---|
| 2021 equity financing | Company announced $120M equity financing | Medium | Shows ability to raise external capital | Request post-money cap table and use-of-funds bridge |
| 2021/2022 Form D activity | Private placements corroborated | High | Funding activity continued after rebrand | Request exact amounts closed and remaining commitments |
| Current cash on hand | null | Low | Main unanswered underwriting variable | Request latest balance sheet |
| Monthly burn | null | Low | Needed for runway months | Request trailing 12-month cash-flow statement |
| Runway months | null | Low | Needed to judge launch dependency | Request board-approved cash runway plan |
| Retail raise 2026 | Weakly supported narrative | Low | Could materially change runway if verified | Request subscription documents and settlement evidence |
Historical funding facts do not substitute for current liquidity disclosure.
[CI006, CI007, CI008, CI016, CI017, CI020]| Missing private metric | Impact | Exact diligence path |
|---|---|---|
| Cash on hand and unrestricted liquidity | Cannot judge runway | Request latest audited balance sheet and treasury schedule |
| Monthly burn and operating cash flow | Cannot judge financing dependency | Request trailing 12-month cash flow by month |
| Preference stack and dilution overhang | Cannot judge incremental financing quality | Request fully diluted cap table and term summaries |
| Recognized revenue from partners | Cannot separate booked revenue from contingent value | Request revenue-recognition memo and contract schedules |
| Launch pricing / payer assumptions | Cannot build revenue model | Request pricing architecture and market-access plan |
These gaps are the main blockers to precise underwriting.
[CI022, CI023, CI024, CI029, CI031, CI035]Only coarse public ranges are defensible for financing facts; runway remains unavailable.
Runway is zero here only as a placeholder for unavailable verified public data, not as a statement that the company has no cash.
[CI003, CI004, CI006, CI016, CI022]4.5 Financial verdict: strategically valuable, operationally under-disclosed
From a financial diligence perspective, Biosplice looks like a company whose value is still driven by probability-weighted future economics rather than present operating quality. The positive side of the case is clear: multi-year clinical investment, real ex-US partner economics, and a product that has at least reached NDA review. The limiting factor is equally clear: public sources do not reveal current cash, burn, realized partner receipts, launch pricing, or the mechanics of the capital stack. That means the right financial verdict is not bearish on ambition, but cautious on underwriteability. The company may be worth a great deal if approval, pricing, and launch align; the public record simply does not let an investor prove that case with precision. Later valuation work should therefore stay scenario-based and strongly conditioned on missing private financial disclosures.[CI018, CI019, CI024, CI025, CI026, CI031]
05Product & Technology
5.1 What the product is in workflow terms
Biosplice is not selling a toolkit or platform subscription to end users. Its lead public product is lorecivivint, a clinician-administered intra-articular injection for knee osteoarthritis. In workflow terms, that means the therapy sits inside specialty orthopedic or rheumatology care and is evaluated through pain, function, and structure outcomes rather than consumer activation metrics. The product architecture is therefore relatively simple at the point of use: identify the right patient, administer a single injection, and follow clinical outcomes over time. The complexity sits upstream in molecular design, trial execution, regulatory review, and launch readiness. That distinction is important because it changes what maturity means. A biotech product can be highly mature scientifically while still being commercially opaque on manufacturing, quality, or support operations. Public sources let this chapter describe the drug, the administration model, and the key evidence loops with confidence.[CE001, CE002, CE005, CE025, CE029]
| User job | Current workflow | Biosplice solution | Measurable benefit | Limitation |
|---|---|---|---|---|
| Treat symptomatic knee OA | Office visit and injection decision | Single intra-articular lorecivivint injection | Pain/function plus possible structure signal | Approval pending |
| Identify dose and responders | Clinical trial dosing and assessment | 0.07 mg selected through earlier studies | Dose focus for late-stage program | Subgroup sensitivity remains |
| Document disease activity | Pain NRS, WOMAC, patient global assessment | Core endpoints reused across studies | Comparable evidence package | Endpoints still produced mixed late-stage results |
| Evaluate structural change | Radiographic mJSW / X-ray | Structure included in program design | Differentiation beyond analgesia | Commercial acceptance of structure claims not settled |
The product workflow is clinical and evidence-heavy rather than digitally instrumented.
[CE001, CE002, CE005, CE006, CE007, CE008]The OA product moves from patient selection to specialist injection to longitudinal outcome follow-up.
[CE001, CE005, CE014, CE029]5.2 Asset map and platform breadth
The company's public product set is broader than a single osteoarthritis asset. Lorecivivint is the lead and the only asset with an NDA filing in the reviewed source set, but the publications and trial record also show oncology programs including SM04755, SM08502, and cirtuvivint. That matters because the underlying platform story is alternative-splicing control across multiple disease areas rather than one-off OA chemistry. It also matters because platform breadth changes how investors should think about technical optionality and management focus. A broader asset map can increase value if learning transfers across programs; it can also create capital-allocation and execution tradeoffs. From a product-and-technology perspective, the right conclusion is that Biosplice has demonstrated enough public breadth to be considered a platform company, but not enough public operational detail to judge how efficiently that platform scales program to program.[CE011, CE012, CE013, CE026, CE030, CE035]
| Asset / module | Primary user | Status / maturity | Differentiation | Diligence gap |
|---|---|---|---|---|
| Lorecivivint (OA) | Injecting specialist | NDA filed / review stage | Potential disease-modifying OA thesis | Launch operations not public |
| SM04690 phase 2 evidence base | Clinical development team | Completed | Dose finding and endpoint architecture | Commercial translation unclear |
| SM04755 oncology | Oncology investigator | Phase 1 completed | Shows broader splicing platform | No clear commercial path in public set |
| SM08502 oncology | Oncology investigator | Terminated study | Broader platform breadth | Business-termination rationale detail limited |
| Cirtuvivint oncology | Oncology investigator / NCI sites | Active study | Platform optionality beyond OA | Economic priority versus OA unclear |
Public asset map supports platform breadth but not equal maturity across programs.
[CE001, CE011, CE012, CE013, CE030, CE035]Clinical maturity is high for OA, while public visibility into commercial operations is low.
[CE011, CE020, CE022, CE032, CE033, CE037]5.3 Mechanism, evidence design, and what the clinical stack actually does
The public mechanism narrative for lorecivivint begins with Wnt-pathway modulation and links that biology to CLK2/DYRK1A inhibition and alternative pre-mRNA splicing. That is the technical core of the company's differentiation claim. The evidence stack built around it is equally important: repeated randomized blinded trials, dose-finding work, and outcome frameworks that combine patient-reported pain/function with structural imaging concepts such as medial joint space width. Public materials show why the program has remained interesting for so long. The product looks strongest when structure and symptoms appear directionally aligned and weakest when all-comer pain endpoints miss despite other signs of activity. That is not just a clinical nuance; it is part of the product design problem because the therapy's real-world value proposition depends on how regulators and payers interpret those endpoints. In that sense, the evidence package is part of the product architecture.[CE003, CE004, CE006, CE007, CE008, CE027]
| Layer / process | Role | Dependency | Risk |
|---|---|---|---|
| Wnt / CLK2-DYRK1A biology | Mechanism foundation | Translational validity | Mechanism may not fully translate to commercial label |
| Single-injection formulation | Delivery approach | Clinician administration | Workflow adoption depends on specialists |
| Randomized blinded trial engine | Evidence generation | Multicenter site network | Execution and endpoint risk |
| Radiographic + PRO endpoint stack | Differentiation proof | Regulatory interpretation | Mixed results can blur product story |
| Regulatory submission package | Path to commercialization | FDA review | NDA outcome unknown |
The evidence package is part of the product architecture for a biotech asset.
[CE004, CE007, CE008, CE014, CE015, CE025]Biosplice's OA product stack combines mechanism, injection delivery, evidence generation, and regulatory review.
[CE001, CE004, CE007, CE010, CE025]The product depends on biology, multicenter trials, regulators, and post-approval operating systems that are only partly visible publicly.
[CE004, CE014, CE017, CE018, CE024, CE036]5.4 Maturity is high in clinical development and low in commercial operations visibility
By biotech standards, the OA asset is mature. The public record includes phase 2, phase 3, and now NDA-stage evidence. Multiple trial records, publications, and company releases provide a clear milestone path from dose finding to pivotal design to regulatory submission. That is a much stronger maturity signal than many venture-stage biotech assets can show. But maturity is uneven. The source set reveals a lot about clinical design and very little about manufacturing, release testing, commercial pharmacovigilance operations, or scaled launch support. That means a report can score the clinical-development machine as advanced while still treating operations and quality readiness as under-disclosed. The gap is not fatal, but it is material because once a program shifts from trial execution to commercialization, the missing details become some of the most important product risks.[CE009, CE010, CE014, CE015, CE023, CE032]
| Date / stage | Milestone | Status | Implication | Source |
|---|---|---|---|---|
| 2015 | ACR mechanism presentation | Completed | Public early mechanism thesis established | ACR 2015 poster |
| 2020 | Phase 2a publication | Completed | Structure + symptom signal documented | Samumed press release / Arthritis & Rheumatology |
| 2021 | Phase 2b publication and post-hoc analysis | Completed | Dose and response case strengthened | Biosplice publications / OARSI article |
| 2022-2024 | Mixed phase 3 disclosures and OA-07 structure update | Completed / mixed | Late-stage proof package remained complex | GlobeNewswire releases |
| 2026 | NDA submission for lorecivivint | Completed milestone | Program entered regulatory review | NDA press release |
Roadmap clarity is highest on clinical milestones and weakest on launch-readiness details.
[CE006, CE009, CE010, CE022, CE032, CE033]5.5 Trust and quality are supported mainly by study design, not by visible operating controls
The strongest public trust signals are scientific and regulatory rather than operational. Randomized, blinded, placebo-controlled studies, peer-reviewed articles, and a steady conference-poster cadence all support the view that Biosplice has built a serious evidence engine around lorecivivint. Safety and tolerability language also appears consistently across the retained sources. What is missing is equally important. The reviewed public set does not reveal commercial-scale manufacturing partners, detailed CMC controls, release metrics, public quality-system certifications, or commercial support infrastructure. That does not mean the controls do not exist; it means outside investors cannot verify them from public sources. For a biotech at NDA stage, this is the core unresolved product-tech issue. The chapter therefore treats study rigor and scientific engagement as verified strengths, while keeping commercialization quality systems and support readiness as explicit diligence gaps rather than inferred strengths.[CE016, CE017, CE018, CE019, CE020, CE021]
| Control / quality signal | Status | Scope | Gap |
|---|---|---|---|
| Randomized, blinded study design | Verified | Core OA trials | Does not prove commercial operations |
| Peer-reviewed publications | Verified | Mechanism and phase 2 evidence | Coverage incomplete for all late-stage data |
| Conference / society presentations | Verified | Practitioner-facing freshness signal | Lower evidentiary weight than papers |
| Public manufacturing / CMC detail | Not visible | Commercial readiness | Major diligence gap |
| Public support / reliability operations | Not visible | Launch readiness | Major diligence gap |
Public trust signals are strongest in science, weakest in post-approval operations.
[CE016, CE017, CE018, CE019, CE020, CE021]06Customers
6.1 Today's practical customers are partners and clinical stakeholders, not commercial users
The biggest challenge in this chapter is definitional. Biosplice does not yet have the kind of public commercial customer base that a software or medical-device company might display. Lorecivivint remained unapproved at the research date, so there is no verified public evidence of production revenue accounts, active commercial treated-patient counts, or payer contracts. The best current proxy for customers is a broader stakeholder set: regional commercialization partners such as Haisco and Samil, clinical investigators and sites that operationalize the studies, and patients whose outcomes create the evidence package. That means the customer chapter is less about installed revenue accounts and more about who is already willing to commit resources, rights, and operating time to the program. This distinction matters because it keeps the analysis honest: Biosplice has real external counterparties and user engagement, but it does not yet have a broad, measurable launched customer base.[CU001, CU002, CU003, CU014, CU017, CU030]
| Segment | Buyer / user / payer | Use case | Scale / strategic value | Gap |
|---|---|---|---|---|
| Haisco | Licensee / local commercial operator / regional payer interfaces | China development and commercialization rights | High strategic value, single named partner | No public revenue-recognition detail |
| Samil | Licensee / local commercial operator / regional payer interfaces | Korea development and commercialization rights | High strategic value, single named partner | No public renewal or receipt detail |
| Clinical investigators and sites | Study operators / users / no payer role | Trial execution and evidence generation | Large operational footprint | Not revenue customers |
| Trial participants / patients | End users under protocol / no buyer role / no payer role | Clinical response generation | Hundreds enrolled across studies | Not commercial treated-patient base |
| Future payers | Prospective buyer-gatekeepers | Coverage and access after approval | Potentially critical | No executed public contracts |
The practical customer map is multi-actor and still mostly pre-commercial.
[CU001, CU006, CU007, CU008, CU017, CU030]The current journey is still pre-commercial: partners and trial stakeholders create the bridge from evidence to future patients.
[CU001, CU002, CU003, CU006, CU025, CU030]Public proof narrows from a broad disease opportunity to a small set of named commercial counterparties.
Last step reflects unavailable public commercial count, not a claim that no off-record patients exist.
[CU001, CU002, CU003, CU017, CU025, CU034]6.2 Named partner proof is the strongest commercialization evidence
Haisco and Samil are the clearest named counterparts in the retained source set. Their agreements matter because they tie lorecivivint to specific geographies and give outside readers something more concrete than a logo wall or a generic business-development claim. Haisco covers China and Samil covers Korea; multiple retained sources corroborate each relationship. This is meaningful evidence that third parties were willing to commit to the asset. At the same time, these deals are still not the same as a mature customer base. They do not prove recurring revenue, renewal rates, or expansion dynamics, and they concentrate the visible partner story into a small number of counterparties. The financial terms are headline values, not proof of realized receipts. So the customer conclusion should be balanced: these relationships show real commercial interest and external validation, but the resulting customer base is narrow and still highly contingent.[CU002, CU003, CU004, CU005, CU020, CU023]
6.3 Patient and site proof is real, but still clinical rather than commercial
The strongest end-user evidence comes from registered trials and post hoc published analyses. Large multicenter OA studies, hundreds of enrolled participants, and named investigators all show that Biosplice can recruit, run, and analyze the program at meaningful scale. The PMC post hoc analysis provides the cleanest patient-level evidence in the retained set, showing a greater likelihood of clinically meaningful pain and function responses in the active-treatment arm. But the customer chapter has to preserve the adverse side too. The placebo-versus-sham analysis reminds readers that intra-articular OA trials can show large control-arm response effects, and the 2026 meta-analysis is more cautious than pure company-authored materials. These are exactly the kinds of nuances that matter when translating clinical enthusiasm into future customer behavior. In short, the evidence supports stakeholder engagement and user interest, but it does not yet prove commercial adoption quality.[CU006, CU007, CU008, CU010, CU011, CU012]
| Metric | Value | Date | Source | Confidence | Implication | Missing denominator |
|---|---|---|---|---|---|---|
| OA-02 enrollment | 455 participants | 2021 update | ClinicalTrials.gov API + study page | High | Early strong patient participation | Commercial conversion |
| STRIDES-1 enrollment | 496 participants | 2026 posted record | ClinicalTrials.gov API + study page | High | Late-stage investigator and patient participation | Commercial conversion |
| Named ex-US partners | 2 geographies (China, Korea) | 2021 deals | Company + independent coverage | High | Partner traction exists | Economic quality of each partnership |
| NCI-sponsored first patient dosed | 1 public activation milestone | 2025 | BioSpace + NCI | Medium | Institutional stakeholder proof beyond OA | Revenue relevance |
Trajectory is milestone-based, not account-based.
[CU002, CU003, CU006, CU007, CU008, CU015]| Customer / stakeholder | Segment | Deployment / use case | Production vs pilot | Outcome | Limitation |
|---|---|---|---|---|---|
| Haisco | Commercialization partner | China rights for lorecivivint | Production-like partner contract | Named geography and economics disclosed | No public proof of realized revenue or launch |
| Samil | Commercialization partner | Korea rights for lorecivivint | Production-like partner contract | Named geography and economics disclosed | No public proof of realized revenue or launch |
| OA trial participants and investigators | Clinical end users / operators | Registered OA studies | Pilot/clinical proof, not commercial | Hundreds enrolled and published outcome analyses | Not paying customers |
| NCI-sponsored AML/MDS trial network | Institutional stakeholder | Operational study activation | Pilot/clinical proof, not commercial | First patient dosed and active study | Not product revenue |
Named proof is strongest where a partner or institution is tied to a specific right or study and corroborated by multiple domains.
[CU002, CU003, CU006, CU007, CU008, CU010]Partner proof is stronger on commercialization intent; clinical proof is stronger on user engagement than on revenue quality.
[CU002, CU003, CU006, CU010, CU015, CU020]Only trial-follow-up style durability is publicly visible; commercial retention remains unknown.
1 values indicate evidence presence for a durability proxy, not a retention percentage.
[CU018, CU019, CU026, CU027]6.4 Retention is mostly a gap; concentration is clearly high
Public retention evidence is weak. There are no disclosed NRR, GRR, churn, contract-renewal, or reorder metrics. Trial follow-up and repeat-dosing designs are useful only as indirect proxies because they capture protocolized engagement rather than true customer willingness to repurchase. By contrast, concentration risk is easy to see. The visible ex-US partner story is concentrated in a small number of named counterparties, and the overall customer narrative is concentrated around one lead OA asset. This does not make the company unattractive, but it makes the customer base under-diversified from a diligence perspective. If approval lands, a small number of partner and payer decisions could matter disproportionately. Until then, the right analytic move is to keep most retention fields null and emphasize concentration, stakeholder type, and next-proof milestones instead.[CU018, CU019, CU023, CU024, CU026, CU027]
| Metric | Value / null | Segment | Confidence | Diligence ask |
|---|---|---|---|---|
| NRR / GRR | null | Partners | Low | Request contract expansion and renewal history |
| Commercial repeat purchasing | null | Patients / providers | Low | Request post-launch reorder expectations or pilot sales data |
| Contract renewals | null | Partners | Low | Request amendment / extension history |
| Trial follow-up durability | Protocol follow-up only | Participants | Medium | Separate protocol retention from real repurchase behavior |
| Patient-reported response durability | 24-week and longer trial signals | Participants | Medium | Map response durability to likely real-world usage thresholds |
Retention proxies exist only inside trials; commercial retention is not publicly visible.
[CU018, CU019, CU026, CU027]| Expansion driver | Concentration risk | Impact | Diligence path |
|---|---|---|---|
| Additional geographies via licensing | Small number of named counterparties | Partner dependence can bottleneck growth | Request BD pipeline and territory plan |
| U.S. approval and launch | Single lead OA asset concentration | Commercial story hinges on one product | Request launch sequencing and backup programs |
| Institutional trial expansion | Clinical proof may not convert to customer diversification | Can overstate true customer breadth | Request payer and prescriber engagement plan |
| Partner milestones / royalties | Receipt timing and realization uncertainty | Financial and customer-quality ambiguity | Request contract schedules and payment history |
Expansion potential exists, but current customer concentration is high.
[CU005, CU023, CU024, CU025, CU032, CU033]6.5 Customer verdict: real stakeholder pull, limited commercial visibility
Biosplice has stronger customer-style evidence than a raw preclinical story, but weaker evidence than a launched commercial company. The partner side is real and named. The patient and investigator side is real and tied to registered studies and publications. Institutional proof extends even to NCI-sponsored work in oncology. What is missing is the full commercial layer: executed payer coverage, active treated commercial patients, repeat purchasing, satisfaction outside trials, and expansion dynamics. The result is a nuanced but coherent verdict. Biosplice appears able to attract serious stakeholders around its lead programs, and that is valuable. It does not yet provide enough public proof to claim a diversified, durable, measurable customer base. That gap should shape later risk and valuation judgments more than the presence of partner logos alone.[CU015, CU016, CU017, CU030, CU032, CU036]
07Risks
7.1 Regulatory and legal risks dominate the current stack
The dominant risks around Biosplice are still regulatory and evidence-related. Lorecivivint has reached NDA review, which is a major achievement, but that stage also concentrates attention on every remaining weakness in the clinical package. Mixed phase 3 outcomes, a documented OA-21 primary-endpoint miss, and an external meta-analysis that is more cautious than company-authored messaging all reinforce that approval is not a formality. On the legal side, public patent assignment records show that Biosplice has meaningful IP assets, but they do not answer enforceability, expiry, or freedom-to-operate questions. More unusually, the apparent absence of working public terms and privacy pages creates a minor but noteworthy governance gap. None of these legal items outrank the approval question, but they belong in the diligence stack because they speak to readiness and external transparency for investors and counterparties. They also help frame where legal diligence should stop relying on surface-level web evidence and move into counsel-led document review.[CR001, CR002, CR003, CR004, CR008, CR009]
| Risk | Jurisdiction / context | Status | Likelihood | Severity | Mitigation | Residual exposure | Diligence path |
|---|---|---|---|---|---|---|---|
| Approval or label risk | FDA / U.S. OA program | Open | Medium | High | NDA submitted with multi-study package | High | Review full NDA and likely label scenarios |
| Mixed late-stage efficacy signal | Clinical evidence package | Present | High | High | Subgroup and structure arguments | High | Inspect full trial reports and sensitivity analyses |
| Patent scope / enforceability uncertainty | IP / legal | Open | Medium | Medium | Visible assignment record | Medium | Commission patent counsel review |
| Missing public privacy / terms surfaces | Web governance / legal hygiene | Present | Medium | Low | Could be fixed quickly | Low-Medium | Confirm formal policies and publication path |
Ordered by current underwriting materiality rather than legal technicality.
[CR001, CR002, CR003, CR008, CR010, CR011]Approval, financing, and access risks dominate residual severity.
[CR001, CR016, CR019, CR023, CR030, CR040]7.2 Operational risk is about opaque commercialization systems, not trial execution ability
Public evidence supports Biosplice's ability to run sophisticated multicenter studies and maintain external scientific engagement. That is the company's clearest operational strength. The problem is that this strength covers development, not necessarily launch. The retained source set does not make manufacturing, CMC, pharmacovigilance, supply chain, or field-support readiness legible. For a late-stage biotech, that omission is material because success after approval depends on systems that are mostly invisible from public materials. The operational risk is therefore asymmetric: the company appears strong enough to get to the decision point, but the same public record does not prove it is ready to commercialize at scale. This is why approval alone cannot clear the full risk stack. The right next diligence step is to inspect the hidden operating machinery, not to keep debating market size. In practical terms, the biggest operational question is whether the company has already done the unglamorous work needed for a controlled commercial launch.[CR012, CR020, CR021, CR022, CR032, CR036]
| Failure mode | Likelihood | Severity | Mitigation maturity | Residual exposure | Unresolved gap |
|---|---|---|---|---|---|
| CMC / manufacturing readiness under-disclosed | Medium | High | Low | High | No public CMC detail |
| Launch support / pharmacovigilance readiness unclear | Medium | High | Low | High | No public support-system checklist |
| Trial-execution-to-launch transition gap | Medium | Medium | Medium | Medium-High | Strong trial ops do not prove launch ops |
| Scientific communication stronger than commercial systems visibility | High | Medium | Medium | Medium | Need launch-readiness package |
Operational proof is stronger in development than in commercialization.
[CR012, CR020, CR021, CR022, CR032, CR036]Clinical and regulatory risk transmit directly into cash, access, and valuation.
[CR002, CR003, CR005, CR016, CR023, CR030]7.3 Partner, customer-access, and financing risks can compound each other
Biosplice's partner structure helps and hurts. Haisco and Samil reduce the loneliness of the commercialization story by showing that external counterparties will sign up for the asset. They also create concentration because there are only a few named partners and because the customer story is still pre-commercial. If those partners underperform or if payer access is weak, the visible monetization lanes narrow quickly. Financial opacity amplifies this risk. Form D activity and financing announcements show repeated access to capital, but they do not reveal current cash, burn, or runway. The weakly supported 2026 retail-raise narrative adds noise rather than clarity. Put together, partner dependence, payer-access uncertainty, and financing opacity are not separate problems; they can reinforce one another if approval timing or launch traction disappoints.[CR013, CR015, CR016, CR017, CR018, CR019]
| Dependency | Counterparty / context | Role | Concentration | Failure scenario | Severity | Mitigation | Residual exposure |
|---|---|---|---|---|---|---|---|
| China partner | Haisco | Regional development / commercialization | High | Execution or milestone underperformance | High | Contractual rights and alternative BD options | High |
| Korea partner | Samil | Regional development / commercialization | High | Slow launch or weak market build | Medium-High | Contract governance and support | Medium-High |
| Payer access | CMS / commercial payers | Coverage and adoption gate | High | Weak reimbursement or coding delay | High | HEOR and access work | High |
| Capital providers | Private investors | Runway and dilution bridge | High | Delay forces financing under pressure | High | NDA de-risking if successful | High |
Partner and financing dependencies intensify one another when timing slips.
[CR013, CR015, CR016, CR017, CR018, CR019]The launch thesis depends on regulators, capital, payers, and a small partner set.
[CR015, CR016, CR019, CR025, CR026, CR027]7.4 Residual exposure remains high until approval, access, and liquidity are all clearer
The right residual-risk view is still conservative. Approval risk is first order, but it is not the only first-order item. Access and pricing readiness are nearly as important because a weak label or slow reimbursement can hollow out the value of an approved drug. Cash-opacity risk is also first order because it determines how much time the company has to absorb delays. Portfolio issues such as the terminated SM08502 study and the limited relevance of oncology institutional proof to OA launch do not dominate the thesis, but they matter because they shape management focus and optionality. The net result is that Biosplice should be judged as a company with real scientific and strategic upside but a concentrated and under-disclosed execution stack. That is exactly the kind of case where clear kill criteria and specific diligence asks matter more than broad enthusiasm. It is precisely the kind of situation where a single unexpected delay can cascade through financing, access, and partner confidence all at once systemwide severely.[CR006, CR007, CR014, CR023, CR029, CR030]
| Role / function | Dependency or gap | Likelihood | Severity | Mitigation | Diligence path |
|---|---|---|---|---|---|
| Regulatory leadership | Must convert mixed package into approvable story | Medium | High | Existing NDA submission | Review regulator interaction history |
| CMC / quality leadership | Launch systems not publicly visible | Medium | High | Unknown publicly | Request org chart and CMC owners |
| Market access leadership | No public payer-proof yet | High | High | Could prepare in parallel | Request payer-readiness materials |
| Portfolio management | Needs to balance OA with oncology optionality | Medium | Medium | Institutional support exists | Review program-prioritization process |
Execution risk clusters around post-NDA transition functions.
[CR006, CR018, CR023, CR033, CR036, CR037]| Risk | Monitorable trigger | Threshold / event | Action implication |
|---|---|---|---|
| Approval risk | FDA decision timing / CRL | Delay or restrictive label | Re-underwrite commercialization and cash needs |
| Financing opacity | Updated cash disclosure | Runway below 12 months at delay point | Assume dilution risk rises materially |
| Payer access risk | Coverage / coding progress | No credible access path post-approval | Cut launch adoption assumptions |
| Partner concentration | Partner milestone performance | Material slippage or dispute | Lower ex-US optionality value |
These are the most thesis-relevant external kill criteria.
[CR023, CR025, CR026, CR027, CR030, CR040]08Valuation
8.1 Recommendation and price discipline
Public evidence supports interest in Biosplice, not a buy decision. The company still has a legitimate late-stage asset, multiple historical financing proofs, and external partners willing to pay meaningful regional economics for lorecivivint. Those facts are real. The problem is price discipline. The most visible valuation anchors are still a 2018 reported $12B private mark and a handful of secondary-market or tracker pages that either reuse old references, rely on undisclosed models, or explicitly label their ownership data as estimated. Meanwhile, the same public record still does not disclose current cash, burn, cap-table preferences, realized partner receipts, launch pricing, or payer readiness. That mismatch matters more than the company's pedigree. A disciplined committee can remain interested while refusing to treat historical prestige or tracker pages as current fair value. The right posture is therefore research-more / track, with the recommendation allowed to improve only if private evidence closes the valuation and liquidity gaps.[CV002, CV003, CV006, CV007, CV008, CV009]
| Dimension | Assessment | Evidence basis | Decision implication |
|---|---|---|---|
| Recommendation | Research-more / track | Late-stage asset and historical financing are real, but current valuation support is indirect | Do not buy on public record alone |
| Confidence | Medium-low | Funding history and regulatory stage are well corroborated; current pricing evidence is not | Require private diligence before IC commitment |
| Risk rating | High | Approval, access, runway, and term opacity remain first-order | Use price and terms discipline |
| Valuation stance | Stretched / under-supported | Trackers point to decacorn context, but fresh primary valuation proof is absent | Anchor to downside protection, not prestige |
| Upgrade trigger | Move only on evidence | Cap table, runway, label, access, and launch package must clear diligence thresholds | Convert interest into buy only if private package is strong |
Recommendation is price-sensitive and evidence-sensitive, not a generic company-quality score.
[CV002, CV003, CV009, CV022, CV023, CV024]| Argument | Evidence support | What would change the view |
|---|---|---|
| Thesis: lorecivivint is a real late-stage asset | NDA filed and still treated as NDA/BLA-stage by retained sources | Actual approval, label breadth, and launch plan |
| Thesis: external partners validated the asset | Haisco and Samil disclosed meaningful regional economics | Evidence that partner economics translate into realized value |
| Thesis: historical funding access was exceptional | 2018 reported $12B mark plus later financing round | Current terms and runway, not only historical prestige |
| Anti-thesis: valuation evidence is stale | Tracker pages lean on old references or opaque models | Signed term sheet with current pricing and investor protections |
| Anti-thesis: economics are opaque | No public revenue, margin, burn, or runway figures | Private financial package with cash bridge and commercialization assumptions |
| Anti-thesis: mixed evidence can compress price | OA evidence is not clean enough for a frictionless premium multiple | Approval plus reimbursement traction and clean post-launch indicators |
Arguments are paired with falsifiable diligence asks rather than treated as permanent truths.
[CV001, CV002, CV014, CV015, CV016, CV021]The call flows from strategic credibility through valuation opacity into a research-more recommendation.
[CV001, CV014, CV015, CV031, CV032, CV039]Compact IC-facing indicators show strategic credibility but weak valuation support.
[CV026, CV031, CV032, CV039, CV041, CV042]8.2 What the public record really supports versus what it only gestures toward
The public record is strongest on historical financing and current strategic stage. MedCity, Tracxn, the 2021 company financing release, and the SEC filing trail make it easy to say Biosplice once commanded an extraordinary private valuation and later raised more capital after the rebrand. Synapse and the NDA announcements make it equally easy to say the lead asset has reached a serious regulatory milestone. What the public record does not support is continuity from those facts to today's price. UpMarket, Notice, Dealroom, Seedtable, and related trackers are useful orientation tools, but they are not substitutes for a signed term sheet or audited financial package. Their disagreements on rounds, investors, or valuation methodology are not fatal; they simply show why this chapter must be scenario-based. A valuation chapter that pretends those pages are primary evidence would overstate certainty. The more honest view is that Biosplice is strategically credible but still priced through an opaque private-market mirror.[CV001, CV002, CV004, CV005, CV006, CV007]
| Comparable | Metric | Multiple / valuation / status | Relevance | Limitation |
|---|---|---|---|---|
| Biosplice 2018 private round | Historical financing mark | Reported $438M round at $12B pre-money | Best-known historic valuation anchor | Stale and pre-NDA; not current fair value |
| Biosplice 2021 financing | Later private financing | Company-announced $120M financing; valuation undisclosed | Shows post-rebrand capital access | No post-money or preference terms disclosed |
| UpMarket / Notice tracker context | Secondary-style private-market signal | UpMarket quotes $12.44B reference and $11B estimate; Notice shows $4.87 share headline | Useful for current market narrative and liquidity framing | Model-driven, indirect, and not a priced round |
| Lorecivivint China licensing | Model-appropriate transaction reference | Up to $140M aggregate value including upfront and milestones | Anchors real external willingness to pay for regional rights | Not enterprise equity valuation |
| Lorecivivint Korea licensing | Model-appropriate transaction reference | Up to $70M aggregate value | Adds second external asset-value reference | Still not enterprise equity valuation |
| Peer baskets from Caplight / VentureRadar / Tracxn | Similarity-based comp set | OrthoTrophix, Kolon TissueGene, Eupraxia, Surrozen, Skyhawk, Frequency, Arrakis and others surfaced as analogs | Useful for peer framing and category placement | Fetched excerpts do not provide a clean matched multiple set |
This is a sample enumeration of valuation-relevant references, not a complete or normalized public-comps table.
[CV002, CV003, CV007, CV008, CV012, CV013]Public valuation references span small partner transactions, total capital raised, and very large tracker marks.
These figures mix transaction values, total capital raised, and tracker-style valuation references; they are displayed together to show how wide the public anchor set is, not to imply equivalence.
[CV002, CV003, CV005, CV007, CV014, CV015]8.3 Scenarios and comparables should bound valuation, not pretend to solve it
The comp set helps bound the discussion, but it does not produce a neat spreadsheet answer. Caplight, VentureRadar, and Tracxn place Biosplice alongside regenerative, RNA, and specialty-biotech peers rather than one clean public-comparable basket. That is directionally useful because it shows how investors and databases classify the company. It is not enough to justify a direct multiple. The more relevant underwriting references are historical financing marks, the Haisco and Samil deal values, the late-stage NDA milestone, and the gap between platform optionality and current commercial opacity. Bull case requires approval, workable reimbursement, and current financing terms that do not trap new capital behind an old private mark. Base case assumes the science and partnering story remain credible, but price must reset to what current disclosure can support. Bear case assumes approval timing slips, payer access is weaker than hoped, or financing must be raised under pressure. Those outcomes produce a very wide valuation envelope by design.[CV012, CV013, CV014, CV015, CV016, CV018]
| Case | Assumptions | Valuation / return logic | Probability signal | Downside trigger |
|---|---|---|---|---|
| Bull | Approval lands, label is commercially usable, access work is credible, and cap-table terms are ordinary | A protected entry below stale decacorn expectations can compound if launch de-risks quickly | Private package confirms runway and launch readiness | Approval delay, adverse label, or stacked preferences |
| Base | Science and partner story remain credible but public metrics stay incomplete | Track or diligenced hold; price should reset to what current disclosure can support | Historical funding plus partner economics keep option value alive | No data-room access or valuation discipline |
| Bear | Approval, access, or financing goes wrong while current mark remains anchored to old prestige | Flat or down-round outcome becomes plausible and upside compresses | Secondary liquidity remains thin and terms are investor-unfriendly | Forced financing or weak reimbursement |
Scenario logic is directional rather than precise because public evidence does not support a clean DCF or revenue-multiple model.
[CV016, CV021, CV023, CV024, CV025, CV033]Public evidence supports a very wide scenario range, not a single fair-value point.
These scenario ranges are underwriting heuristics tied to approval, access, dilution, and disclosure outcomes; they are not company guidance or market quotes.
[CV033, CV034, CV035, CV037, CV038, CV039]8.4 The final decision should turn on private disclosures, not more narrative
At this point the highest-value work is not another generic market survey. It is private diligence. The decisive asks are straightforward: current post-money and ownership, liquidation preferences, option-pool expansion, current cash and burn, board runway plan, label scenarios, reimbursement assumptions, launch-readiness evidence, and proof that the regional deal economics are translating into real strategic leverage rather than old press-release headlines. If those materials show ordinary terms, adequate runway, and credible commercialization readiness at a materially lower or better-protected entry, the recommendation can improve quickly. If they show stress, stacked preferences, or thin liquidity, the thesis should break just as quickly. That makes Biosplice a price-sensitive research-more case rather than a permanent pass. The public evidence says there is something worth diligencing; it does not yet say there is a public-record basis to buy at a decacorn-style mark.[CV021, CV022, CV023, CV024, CV028, CV032]
| Trigger | Threshold | Transmission to thesis | Action implication |
|---|---|---|---|
| Approval or label disappointment | Meaningful delay or label narrower than commercial plan requires | Undercuts core value driver and extends financing risk | Pause investment or demand repriced terms |
| Cash or runway weakness | Runway insufficient to absorb launch or regulatory slippage | Forces valuation discussion into dilution protection rather than upside | Require bridge plan or walk |
| Preference overhang | Stacked preferences, aggressive pay-to-play, or large option-pool reset | Can erase headline upside for new investors | Reprice or decline |
| Weak reimbursement plan | No credible coding, access, or HEOR strategy | Turns approved drug into slow or low-value launch | Delay commitment until access proof exists |
| Partner underperformance | Regional partners fail to execute or economics prove less valuable than advertised | Shrinks optionality and removes external validation | Lower scenario weights and valuation range |
Kill criteria are intentionally monitorable and tied to underwriteable events.
[CV016, CV022, CV023, CV024, CV033, CV035]| Topic | Missing evidence | Why it matters | Owner or diligence path |
|---|---|---|---|
| Current valuation and terms | Signed term sheet, current post-money, liquidation preferences, option-pool plan | Turns tracker narratives into real entry math | Lead investor counsel + CFO diligence |
| Liquidity and runway | Current cash, burn, runway bridge, and downside scenario model | Determines whether delays create forced financing | Board package and CFO review |
| Commercial assumptions | Launch price corridor, reimbursement plan, and access milestones | Needed to translate approval into revenue value | Commercial lead + market-access review |
| Launch readiness | CMC, supply chain, medical affairs, and pharmacovigilance package | Operational readiness can destroy equity value even after approval | Quality/regulatory diligence |
| Partner value realization | Haisco and Samil milestone status, receipts, amendments, and governance | Shows whether disclosed deal values are real economic support | BD/legal diligence |
The shortest path to a better recommendation is better private evidence, not more public tracker screenshots.
[CV014, CV015, CV022, CV023, CV024, CV032]Disclaimer
This report is a public-source diligence aid as of 2026-08-18 and is not investment advice. Biosplice’s current valuation, capitalization, and operating metrics remain privately held; figures tied to historical marks or tracker pages should be treated as directional context until confirmed in primary transaction and financial materials.
Evidence index
| ID | Statement | Confidence | Sources |
|---|---|---|---|
| CO001 | Biosplice Therapeutics is a private clinical-stage biotechnology company headquartered in San Diego, California. | Medium | SO002, SO001 |
| CO002 | Dealroom dates Biosplice's founding to 2008. | Medium | SO023 |
| CO003 | Biosplice focuses on first-in-class small-molecule therapeutics linked to CLK/DYRK kinase modulation and alternative RNA splicing. | Medium | SO001, SO007, SO016 |
| CO004 | Public materials position lorecivivint for knee osteoarthritis as Biosplice's lead program. | Medium | SO001, SO007, SO009 |
| CO005 | Current public management materials name Erich Horsley as chief executive officer. | Medium | SO004, SO005 |
| CO006 | Current public management materials name Osman Kibar as founder and executive chairman. | Medium | SO004, SO005, SO024 |
| CO007 | Current public management materials name Yusuf Yazici as chief medical officer. | Medium | SO004, SO024 |
| CO008 | Current public management materials name Phil Wilson as chief financial officer. | Medium | SO004, SO024 |
| CO009 | Current public management materials name Scott W. Bulcao as chief legal officer. | Medium | SO004, SO024 |
| CO010 | The public board page lists Finian Tan of Vickers Venture Partners as a director. | Medium | SO005 |
| CO011 | The public board page lists Stephen Zachary of Sands Capital as a director. | Medium | SO005 |
| CO012 | The public board page lists Ahmed Khizer Khan of Daman Investments as a director or board advisor. | Medium | SO005 |
| CO013 | Biosplice announced a $120 million equity financing on April 15, 2021. | Medium | SO016, SO021 |
| CO014 | Biosplice said the 2021 financing proceeds would support lorecivivint plus oncology and neurology programs. | Medium | SO016 |
| CO015 | The 2021 financing announcement identified Eventide, aMoon, SymBiosis II, Sands Capital, and Verition among new investors. | Medium | SO016, SO026 |
| CO016 | The SEC shows BioSplice Therapeutics filed a Form D on March 3, 2021. | Medium | SO021, SO020 |
| CO017 | The SEC shows BioSplice Therapeutics filed another Form D on August 24, 2022. | Medium | SO022, SO020 |
| CO018 | Biosplice licensed China development and commercialization rights for lorecivivint to Haisco in September 2021. | Medium | SO013, SO014 |
| CO019 | Biosplice said the Haisco transaction carried $140 million of aggregate value including $20 million of upfront payment and early development milestones. | Medium | SO013, SO014 |
| CO020 | Biosplice also licensed Korean rights for lorecivivint to Samil in 2021. | Medium | SO015 |
| CO021 | In November 2022 Biosplice reported that earlier phase 3 trials OA-10 and OA-11 missed their primary 12-week pain endpoint in all-comers. | Medium | SO012 |
| CO022 | The same 2022 announcement said OA-07 showed structural and pain signals that informed the design of OA-21. | Medium | SO012 |
| CO023 | Biosplice said it discussed OA-21 with FDA in the third quarter of 2022 before planned enrollment. | Medium | SO012 |
| CO024 | In November 2023 Biosplice presented OA-07 extension results showing structure benefit and symptomatic benefit over multiple annual injections. | Medium | SO011 |
| CO025 | The 2023 OA-07 release reported a 0.15 mm advantage versus the last observed placebo comparison and 0.26 mm versus extrapolated placebo progression at 36 months. | Medium | SO011 |
| CO026 | In April 2024 Biosplice disclosed that OA-21 did not meet its 12-week primary endpoint for pain reduction. | Medium | SO010 |
| CO027 | The April 2024 release nevertheless said OA-07 final analysis confirmed statistically significant pain, function, and structural benefit. | Medium | SO010 |
| CO028 | In January 2026 Biosplice announced submission of a new drug application for lorecivivint to FDA. | Medium | SO009, SO017, SO018 |
| CO029 | The January 2026 NDA announcement said lorecivivint had been evaluated in 11 clinical trials and in more than 1,800 dosed patients. | Medium | SO009, SO018 |
| CO030 | Drugs.com still described lorecivivint as investigational and not FDA approved as of the research date. | Medium | SO018 |
| CO031 | ClinicalTrials.gov search results show Biosplice-sponsored studies spanning osteoarthritis, hair loss, and oncology indications. | Medium | SO019, SO030 |
| CO032 | The Synapse organization overview describes Biosplice as having pipeline activity across osteoarthritis, cancer, diabetes, traumatic brain injury, and other degenerative conditions. | Medium | SO030 |
| CO033 | Dealroom labels Biosplice a San Diego biotech founded in 2008 and describes it as medical research and development for tissue-level regeneration. | Medium | SO023 |
| CO034 | Seedtable lists five current executives and three public board members on its public Biosplice profile. | Medium | SO024 |
| CO035 | Caplight publicly shows Biosplice funding-round entries for April 2016, August 2018, and April 2021. | Medium | SO025 |
| CO036 | Dealroom, Caplight, and other trackers preserve Biosplice's 2018-era decacorn narrative but do not provide a fresh public price discovery event after 2021. | Medium | SO023, SO025, SO027 |
| CO037 | The careers page shows no open job postings at the time of review. | Medium | SO003 |
| CO038 | The careers page and public contact materials point to a single San Diego headquarters and do not substantiate a broad multi-office operating footprint. | Medium | SO003, SO002 |
| CO039 | The 2026 retail-investor fundraising narrative is supported only by low-reputation third-party coverage and is not confirmed on Biosplice's official news page. | Low | SO028, SO008 |
| CO040 | UpMarket shows a live private-market profile for Biosplice shares aimed at accredited investors, indicating at least some secondary-market interest. | Low | SO027 |
| CO041 | SymBiosis presents Biosplice as a portfolio company, corroborating its presence in specialist biotech investor networks. | Medium | SO029 |
| CO042 | No official Biosplice press release or SEC filing in the reviewed set publicly confirms a 2026 $500 million-plus retail raise. | Low | SO008, SO020 |
| CM001 | Biosplice is not pursuing the whole arthritis market; its near-term commercial focus is knee osteoarthritis treated by injection rather than systemic arthritis care. | Medium | SM001, SM002, SM013 |
| CM002 | The company frames lorecivivint as a potential disease-modifying osteoarthritis therapy rather than a short-duration analgesic. | Medium | SM001, SM002 |
| CM003 | The Biosplice osteoarthritis page cites roughly 51.9 million U.S. adults and 527.8 million adults globally with osteoarthritis. | Medium | SM001 |
| CM004 | The January 2026 NDA release cites roughly 50 million U.S. adults and over 500 million adults globally with osteoarthritis. | Medium | SM002, SM024 |
| CM005 | The Biosplice osteoarthritis page cites about 24.7 million U.S. adults with knee osteoarthritis. | Medium | SM001 |
| CM006 | The January 2026 NDA release cites about 25 million Americans with knee osteoarthritis. | Medium | SM002 |
| CM007 | The Global Burden of Disease 2021 analysis projects continued growth in osteoarthritis prevalence through 2050. | Medium | SM007 |
| CM008 | CDC FastStats and NIAMS both describe arthritis and osteoarthritis as large and durable public-health burdens in the United States. | Medium | SM005, SM006 |
| CM009 | OARSI characterizes osteoarthritis as a serious disease rather than a minor quality-of-life condition. | Medium | SM008, SM002 |
| CM010 | NICE guidance places exercise, weight management, analgesia, injections, and surgery on the treatment pathway before a novel DMOAD would become routine care. | Medium | SM013, SM014 |
| CM011 | Arthritis Foundation and NIAMS materials show that OA care is still organized around symptom management and function preservation rather than disease reversal. | Medium | SM012, SM006 |
| CM012 | ClinicalTrials.gov and company materials show Biosplice repeatedly emphasizing earlier-stage KL2 and early KL3 patients as the subgroup with the clearest signal. | Medium | SM004, SM010 |
| CM013 | The 2022 Biosplice release said earlier, less structurally damaged patients represented roughly 70% of the knee OA population studied by the company. | Medium | SM004 |
| CM014 | If the 25 million U.S. knee OA figure and the 70% earlier-stage subgroup assumption are both directionally correct, the company's preferred subgroup implies a candidate population around 17.5 million people before payer and contraindication filters. | Medium | SM002, SM004 |
| CM015 | The main user of lorecivivint would be the injecting clinician, while the buyer and payer functions would sit with health systems and insurers rather than the patient alone. | Medium | SM013, SM014, SM011 |
| CM016 | The once- or twice-yearly intra-articular delivery model implies adoption through orthopedics, sports medicine, and rheumatology workflows rather than retail pharmacy self-administration. | Medium | SM001, SM011, SM023 |
| CM017 | Zilretta, Synvisc-One, Monovisc, and Durolane exemplify the incumbent non-surgical injection set lorecivivint must displace or sit alongside. | Medium | SM015, SM017, SM019, SM021 |
| CM018 | Pacira positions Zilretta around OA knee pain relief rather than structure modification. | Medium | SM015, SM016 |
| CM019 | Synvisc-One and Monovisc are positioned as viscosupplement injections, again emphasizing symptom relief and mobility rather than disease modification. | Medium | SM017, SM018, SM019, SM020 |
| CM020 | Biosplice's market thesis depends on convincing payers and clinicians that a structure-modifying product deserves adoption despite a treatment pathway already crowded with symptom-focused injections and conservative care. | Medium | SM001, SM013, SM017, SM015 |
| CM021 | The April 2024 release disclosed that OA-21 did not meet its 12-week primary endpoint for pain reduction, underscoring that placebo response and endpoint selection remain commercial as well as clinical constraints. | Medium | SM003 |
| CM022 | The 2022 release similarly acknowledged that OA-10 and OA-11 fell short on their primary all-comer pain endpoints even while subgroup signals looked better. | Medium | SM004 |
| CM023 | The 2026 NDA filing means Biosplice has progressed farther than most OA drug developers, but FDA approval remained pending at the research date. | Medium | SM002, SM011 |
| CM024 | Public evidence supports multiple prevalence lenses, but not a single clean public SAM or SOM in annual dollar terms. | Medium | SM007, SM005, SM013 |
| CM025 | ClinicalTrials.gov shows a substantial development footprint around lorecivivint, which helps validate market seriousness even if it does not prove payer acceptance. | Medium | SM009, SM010 |
| CM026 | The OA-11 study record confirms that Biosplice tested a phase 3 population of 40-80 year old adults with symptomatic knee OA, reinforcing that the commercial target lies within a common older-adult chronic-disease workflow. | Medium | SM010 |
| CM027 | Arthritis Foundation and NIAMS both present osteoarthritis as chronic, mobility-limiting, and highly prevalent, supporting durable long-term demand if an effective therapy clears the evidence bar. | Medium | SM012, SM006 |
| CM028 | NICE and NCBI guidance imply that any premium-priced new injection would need to prove superiority or meaningful differentiation against conservative management and incumbent injectables. | Medium | SM013, SM014, SM015 |
| CM029 | The ACR on Air episode centered on lorecivivint publications indicates at least some rheumatology-community attention, but not yet broad real-world adoption proof. | Medium | SM023, SM003 |
| CM030 | Broad analyst dollar-TAM narratives are weaker than prevalence-led market sizing because public sources disagree on exactly which spending categories belong inside the addressable market. | Medium | SM013, SM006, SM011 |
| CM031 | The market chapter should therefore treat prevalence and workflow penetration as the primary sizing logic and preserve dollar-SAM uncertainty as an explicit diligence gap. | Medium | SM007, SM013, SM011 |
| CM032 | Global OA burden can be framed at roughly 500 million-plus adults, U.S. OA burden at roughly 50 million-plus adults, and U.S. knee OA burden at roughly 25 million adults. | Medium | SM001, SM002, SM007 |
| CM033 | The addressable care path excludes rheumatoid arthritis biologics, general orthopedic hardware, and unrelated chronic-pain spend. | Medium | SM013, SM006 |
| CM034 | Payers remain crucial because guideline placement and reimbursement determine whether a novel injection reaches routine use beyond specialty centers. | Medium | SM013, SM011 |
| CM035 | Status-quo substitutes include exercise and weight management, oral or topical analgesics, steroid injections, hyaluronic-acid injections, and eventual arthroplasty. | Medium | SM013, SM006, SM017, SM015 |
| CM036 | A key adoption constraint is that the market already tolerates lower-evidence symptomatic care, which can make premium reimbursement for a novel agent difficult even when unmet need is real. | Medium | SM013, SM011, SM012 |
| CM037 | A key growth driver is the combination of aging populations, obesity-linked joint damage, and a lack of approved disease-modifying OA drugs. | Medium | SM007, SM006, SM008 |
| CM038 | Biosplice's commercial story is strongest if regulators and payers accept structure plus symptom benefit as a materially better proposition than incumbent pain-focused injections. | Medium | SM002, SM003, SM015, SM017 |
| CM039 | Public evidence does not yet quantify real-world physician uptake, payer coverage, or price elasticity for lorecivivint because the product remains unapproved. | Medium | SM011, SM002 |
| CM040 | Because the product remains unapproved, the practical SOM today is zero realized commercial patients even though the candidate population could be large. | Medium | SM011, SM002 |
| CM041 | No reviewed primary public source provides a clean, company-specific annual revenue TAM for Biosplice's knee OA opportunity. | Medium | SM013, SM007, SM006 |
| CP001 | Public evidence still shows no approved disease-modifying osteoarthritis drug, so Biosplice competes mainly against symptom-focused incumbents and surgical deferral pathways rather than a like-for-like DMOAD peer. | High | SP001, SP002, SP019 |
| CP002 | Zilretta is positioned around osteoarthritis knee pain relief as an extended-release corticosteroid, not around structural modification. | Medium | SP007, SP008 |
| CP003 | Synvisc-One, Monovisc, Orthovisc, Euflexxa, and Hyalgan are all marketed as hyaluronic-acid or sodium-hyaluronate injections for knee-OA pain relief. | High | SP009, SP011, SP014, SP015, SP016 |
| CP004 | Cingal combines hyaluronic acid with steroid, showing that incumbents already experiment with convenience-plus-speed positioning even without claiming disease modification. | Medium | SP017 |
| CP005 | AAOS and OrthoInfo materials show that conservative care and eventual total knee replacement remain important substitutes around any new injectable therapy. | High | SP019, SP018 |
| CP006 | OrthoInfo says more than 700,000 total knee replacements are performed annually in the United States, underscoring the scale of the downstream substitute pathway. | Medium | SP018 |
| CP007 | Biosplice attempts to differentiate lorecivivint by arguing for both pain/function benefit and structural benefit, which is a different message from incumbent injection brands. | Medium | SP001, SP002, SP003 |
| CP008 | That differentiation story is weakened by Biosplice's own disclosure that OA-21 missed its 12-week primary pain endpoint. | Medium | SP003 |
| CP009 | The 2022 company release also acknowledged mixed all-comer outcomes in OA-10 and OA-11, which means Biosplice is not entering the market with an unambiguously superior clinical record. | High | SP004, SP006 |
| CP010 | Because lorecivivint remained pending at the FDA as of the research date, incumbent products still own the trust, coding familiarity, and routine-office workflow advantages. | Medium | SP002, SP007, SP009, SP015 |
| CP011 | Monovisc and Orthovisc materials show Anika products competing on dosing convenience and clinical familiarity, while J&J MedTech helps distribute Monovisc and the Orthovisc page says its U.S. syringe is distributed exclusively by J&J MedTech. | Medium | SP011, SP012, SP014 |
| CP012 | Euflexxa explicitly advertises Medicare Part B coverage without restrictions, signaling that reimbursement familiarity is already part of incumbent positioning. | Medium | SP015 |
| CP013 | Orthovisc claims over 21 million injections worldwide, an adoption signal that newcomer Biosplice cannot yet match commercially. | Medium | SP014 |
| CP014 | Hyalgan presents decades of studies and approval history, illustrating how legacy products can compete on longevity and familiarity rather than innovation. | Medium | SP016 |
| CP015 | The practical buying job is therefore not only efficacy selection but also choosing between familiar reimbursed pain-relief tools and an unproven new category. | Medium | SP015, SP007, SP002 |
| CP016 | Biosplice does not need to displace total knee replacement for all patients; it more plausibly needs to become an earlier escalation step for patients trying to delay surgery. | Medium | SP001, SP018, SP002 |
| CP017 | Switching costs arise from physician habit, payer prior-authorization logic, injection procedure workflows, and the absence of public price transparency for many incumbents. | Medium | SP019, SP015, SP009 |
| CP018 | Public competitor pages emphasize packaging and regimen differences: single injection for products like Monovisc and Synvisc-One versus multi-injection regimens for Orthovisc and Euflexxa/Hyalgan. | High | SP011, SP009, SP014, SP015, SP016 |
| CP019 | Those packaging differences matter because a novel product can win on convenience even before it wins on health-economic proof. | Medium | SP011, SP014, SP017 |
| CP020 | Publicly reviewed competitor sources rarely provide reliable net pricing, which limits any precise price-to-value comparison in this chapter. | Medium | SP007, SP009, SP015, SP016 |
| CP021 | The chapter should therefore treat dosing, indication framing, and channel familiarity as better-supported comparison axes than absolute list price. | Medium | SP011, SP014, SP015 |
| CP022 | ClinicalTrials.gov shows Biosplice is also advancing oncology splicing programs, including SM04755 and cirtuvivint studies, so the company is strategically broader than a single OA asset. | Medium | SP020, SP022, SP023 |
| CP023 | The SM08502 combination study was terminated for business reasons, which is an adverse signal that portfolio focus and capital allocation can shift. | Medium | SP021 |
| CP024 | The AML/MDS cirtuvivint study remained active and Biospace reported first patient dosing in an NCI-sponsored trial, which supports ongoing oncology optionality rather than abandonment. | Medium | SP022, SP023, SP024 |
| CP025 | That optionality is double-edged for OA investors: it can diversify platform value, but it can also divide leadership attention and capital while lorecivivint still needs launch execution. | Medium | SP021, SP022, SP002 |
| CP026 | DrugPatentWatch adds only weak public proof on lorecivivint IP and should be treated as a low-confidence pointer rather than a moat conclusion. | Low | SP025 |
| CP027 | If approval lands, Biosplice's moat would come primarily from differentiated clinical claims and first-mover status in a new category, not from an already-entrenched commercial channel. | Medium | SP002, SP003, SP019 |
| CP028 | If approval slips or the label is narrow, incumbents with familiar reimbursement and office workflows could blunt that moat quickly. | Medium | SP002, SP003, SP015, SP011 |
| CP029 | Existing vendor-authored comparison surfaces are useful for packaging facts but not independent proof of superiority, so unsupported cells in the matrix should remain explicitly unknown. | Medium | SP007, SP009, SP014 |
| CP030 | The most defensible direct-competition framing is: incumbents for pain relief, surgery for downstream substitution, and no approved direct DMOAD peer yet. | Medium | SP007, SP009, SP018, SP002 |
| CP031 | Incumbent categories split into corticosteroid, hyaluronic-acid, HA-plus-steroid combo, conservative-care substitutes, and surgery. | Medium | SP007, SP009, SP017, SP019, SP018 |
| CP032 | Biosplice's chief advantage claim is disease-modification potential, while its chief disadvantage is lack of approved commercial proof. | Medium | SP001, SP002, SP003 |
| CP033 | Competitor channel power is strongest where products are already integrated into specialist injection workflows and payer coverage precedents. | Medium | SP015, SP012, SP008 |
| CP034 | Single-injection incumbents may be closer analogs for convenience comparison, while multi-injection incumbents highlight follow-up burden and workflow stickiness. | Medium | SP011, SP009, SP014, SP016 |
| CP035 | Biosplice's oncology pipeline broadens the company profile but does not directly solve the knee-OA treatment job, so it belongs in strategic-direction context rather than the direct-rival set. | Medium | SP020, SP022, SP002 |
| CP036 | The most serious displacement risks are clinical underperformance, narrow label scope, payer resistance, and a quick incumbent response on convenience or contracting. | Medium | SP003, SP015, SP011 |
| CP037 | No reviewed source proves robust clinician multi-homing shares across products, so market-share style switching estimates should remain out of scope. | Medium | SP009, SP014, SP015 |
| CP038 | Because public pricing data are thin, competitive readiness is better scored on approval status, indication fit, dosing convenience, and reimbursement familiarity. | Medium | SP002, SP015, SP011, SP014 |
| CP039 | On balance, Biosplice looks differentiated on thesis but weaker than incumbents on trust, reimbursement familiarity, and demonstrated commercial durability. | Medium | SP002, SP003, SP015, SP014 |
| CI001 | Public sources still support a pre-revenue commercial profile: lorecivivint remained unapproved at the research date and no product sales are disclosed. | High | SI001, SI017, SI018 |
| CI002 | The clearest public monetization lanes are partnership economics, not recognized product revenue. | Medium | SI003, SI004, SI012 |
| CI003 | Biosplice's Haisco transaction was described as up to $140 million including $20 million in upfront and early development milestones. | High | SI003, SI012, SI011 |
| CI004 | Biosplice's Samil transaction was described as up to $70 million in aggregate value for Korea rights. | High | SI004, SI013, SI015 |
| CI005 | Those partnership figures describe contingent deal value, not necessarily realized cash receipts or recognized revenue. | Medium | SI003, SI004, SI012 |
| CI006 | The April 2021 company financing release said Biosplice closed $120 million in equity financing to advance clinical programs. | Medium | SI002 |
| CI007 | The 2021 and 2022 Form D filings corroborate that Biosplice continued to use private-placement financing instruments, but do not supply an audited cash balance or burn schedule. | High | SI005, SI006 |
| CI008 | The 2018 Samumed Form D filing underscores that the company has relied on private capital formation for years before the Biosplice rebrand. | Medium | SI007 |
| CI009 | Because the lead OA asset is only now at NDA review, forward revenue remains highly dependent on regulatory approval, label scope, reimbursement, and launch execution. | Medium | SI001, SI016, SI019, SI020 |
| CI010 | Public sources do not provide a credible launch price or contract model for lorecivivint today. | Medium | SI001, SI018 |
| CI011 | For an unapproved biotech product, classic SaaS-style sales-efficiency metrics such as CAC or payback are not supportable from public evidence. | Medium | SI001, SI003 |
| CI012 | The most defensible GTM proxy is partner geography and licensing structure rather than customer acquisition efficiency. | Medium | SI003, SI004 |
| CI013 | Ex-US monetization is visible through China and Korea licensing, while U.S. commercialization economics remain mostly undisclosed. | Medium | SI003, SI004, SI012 |
| CI014 | The public cost structure almost certainly includes clinical development, regulatory work, and pre-launch manufacturing scale-up, but audited expense lines are not disclosed in the retained sources. | Medium | SI001, SI019, SI002 |
| CI015 | Gross margin, COGS, inventory build, and working-capital requirements are all effectively private-evidence-only at this stage. | Medium | SI001, SI018 |
| CI016 | The clearest public capital-adequacy conclusion is not that Biosplice is fully funded, but that it has historically needed repeated external financing to keep multi-year clinical programs moving. | High | SI002, SI005, SI006, SI007 |
| CI017 | The NDA filing may improve financing leverage, but it does not itself prove sufficient cash to complete launch preparations. | Medium | SI001, SI016, SI002 |
| CI018 | Notice presents a secondary-market style stock price and valuation context, but this is not equivalent to audited intrinsic value or a new priced financing round. | Medium | SI008 |
| CI019 | Private-market tracker pages such as UpMarket, Caplight, Dealroom, and Seedtable are useful context but are too indirect to substitute for current audited financial statements. | Medium | SI021, SI022, SI023, SI024 |
| CI020 | The PlainPatent and Justia records show that Biosplice has a real patent asset base, but patent volume does not solve current cash-opacity or near-term margin questions. | Medium | SI009, SI010 |
| CI021 | The reported 2026 retail-investor raise remains weakly supported relative to official company and filing evidence and should not be treated as a verified cash source. | Medium | SI025, SI001, SI006 |
| CI022 | No retained public source quantifies realized royalties, milestone receipts, or deferred-revenue accounting from Haisco or Samil. | Medium | SI003, SI004, SI013 |
| CI023 | No retained public source quantifies monthly burn, runway months, or cash on hand. | Medium | SI005, SI006, SI002 |
| CI024 | No retained public source quantifies launch pricing, gross-to-net assumptions, or reimbursement economics for lorecivivint. | Medium | SI001, SI008 |
| CI025 | The financial chapter can support a partnership-led monetization model and a financing-dependent operating model, but not a precise near-term revenue forecast. | Medium | SI003, SI004, SI005, SI001 |
| CI026 | In financial terms, Biosplice looks like a late-stage biotech whose value is driven by approval probability and licensing optionality rather than present operating cash generation. | Medium | SI001, SI003, SI004, SI008 |
| CI027 | Public monetization categories are U.S. future product sales, ex-US licensing economics, and possible milestones or royalties. | Medium | SI001, SI003, SI004 |
| CI028 | Public pricing visibility today is effectively zero for realized lorecivivint economics. | Medium | SI001, SI008 |
| CI029 | Capital intensity is elevated because Biosplice has advanced a long clinical program and still faces regulatory-review and launch-preparation costs. | Medium | SI002, SI019, SI020 |
| CI030 | The company overview funding chronology is directionally useful, but financial underwriting still needs current cash, burn, and preference-stack documents. | Medium | SI005, SI006, SI008 |
| CI031 | Because there are no product-sales disclosures, every public financial scenario should be labeled estimated or unavailable rather than precise. | Medium | SI001, SI008, SI021 |
| CI032 | Licensing announcements provide geographic and headline-value clues but no recognized-revenue waterfall. | Medium | SI003, SI004, SI011 |
| CI033 | If approval lands, the most likely first visible economics are milestone, launch-investment, and pricing disclosures rather than immediate high-quality recurring revenue. | Medium | SI001, SI016, SI003 |
| CI034 | Secondary-market and tracker pages may indicate investor interest, but none of them eliminate the need for audited financial statements and current cap-table data. | Medium | SI008, SI022, SI023, SI024 |
| CI035 | The current public record is sufficient to call Biosplice capital intensive and financing dependent, but insufficient to call it well capitalized. | Medium | SI002, SI005, SI006, SI001 |
| CI036 | Overall financial quality is constrained less by lack of strategic ambition than by lack of current audited operating metrics. | Medium | SI005, SI001, SI008 |
| CE001 | Biosplice's lead delivered product is a healthcare-professional-administered intra-articular injection of lorecivivint for knee osteoarthritis. | High | SE001, SE018, SE019 |
| CE002 | ClinicalTrials.gov records show the OA program converged on a single 0.07 mg lorecivivint dose delivered in 2 mL vehicle for late-stage trials. | High | SE018, SE019 |
| CE003 | Earlier phase 2 studies explored multiple dose arms before the company narrowed onto the 0.07 mg dose. | High | SE016, SE017, SE023 |
| CE004 | Public Biosplice materials describe lorecivivint as a small-molecule CLK2/DYRK1A inhibitor and Wnt pathway modulator. | High | SE009, SE023, SE025 |
| CE005 | The product workflow is local joint injection rather than chronic systemic administration, which shapes both convenience and safety positioning. | Medium | SE001, SE016, SE018 |
| CE006 | The phase 2b OA paper reported efficacy on patient-reported outcomes and identified 0.07 mg as the lowest effective dose for future studies. | High | SE023, SE003 |
| CE007 | Phase 2a and phase 2b materials emphasize both pain/function outcomes and radiographic measures such as medial joint space width, showing that the product story blends symptom and structure claims. | High | SE005, SE016, SE023 |
| CE008 | STRIDES-1 prioritized patient-reported pain at Week 12, while STRIDES-X-ray emphasized radiographic structure alongside pain and function measures. | High | SE018, SE019 |
| CE009 | Biosplice's own later releases show that the program's maturity is meaningful but not cleanly linear, because mixed phase 3 pain results sat alongside longer-term structural claims. | Medium | SE006, SE007, SE008 |
| CE010 | The January 2026 NDA filing marks a product-stage transition from clinical development to regulatory review for lorecivivint. | Medium | SE008 |
| CE011 | The public asset map also includes oncology splicing programs such as SM04755 and cirtuvivint, making the platform broader than one OA asset. | Medium | SE002, SE020, SE022 |
| CE012 | The SM08502 combination study adds another oncology asset to the public pipeline even though that specific study was later terminated for business reasons. | Medium | SE021 |
| CE013 | The active NCT06484062 AML/MDS study indicates the company still advances cirtuvivint in hematologic malignancy with NCI-linked support. | Medium | SE022 |
| CE014 | The public operating model in OA depends on broad multicenter trial execution across many U.S. sites rather than bespoke hospital deployment. | Medium | SE017, SE018, SE019 |
| CE015 | That site-network dependence means operational readiness is partly a trial-operations and evidence-package problem, not purely a molecule-design problem. | Medium | SE017, SE018, SE008 |
| CE016 | Public sources repeatedly describe lorecivivint as safe and well tolerated, but the chapter still relies mostly on trial summaries and publications rather than detailed safety datasets. | High | SE003, SE005, SE023 |
| CE017 | ClinicalTrials.gov records show randomized, blinded, placebo-controlled OA trial designs, which are trust-supporting process controls for evidence generation. | High | SE016, SE017, SE018, SE019 |
| CE018 | No reviewed public source provides detailed commercial-scale manufacturing, supply-chain, or CMC disclosure for lorecivivint. | Medium | SE001, SE002, SE008 |
| CE019 | No reviewed public source provides a public status page, uptime metric, or commercial support-operation disclosure analogous to software infrastructure companies. | Medium | SE001, SE002 |
| CE020 | The ACR and OARSI poster trail shows a sustained practitioner-facing publication cadence around lorecivivint and related programs from 2015 through 2025. | Medium | SE009, SE010, SE013, SE014, SE015 |
| CE021 | That practitioner-facing cadence is a reasonable developer-signal proxy for a biotech platform that does not expose a public code repository or API community. | Medium | SE002, SE009, SE010 |
| CE022 | Peer-reviewed publications carry more evidentiary weight than conference posters, but the poster sequence is still useful for roadmap freshness and scientific engagement. | Medium | SE023, SE025, SE010, SE013 |
| CE023 | External literature across Sage, Taylor & Francis, and OARSI sources shows independent scientific discussion around lorecivivint and OA disease-modification questions, broadening the technical context beyond company-authored materials. | Medium | SE026, SE027, SE029 |
| CE024 | CDC arthritis statistics reinforce that Biosplice is building for a large chronic disease context, but they do not solve the chapter's missing manufacturing and launch-readiness evidence. | Medium | SE028, SE029 |
| CE025 | The 2020 through 2021 publication set supports early technical maturity, while 2022 through 2026 materials show the program grappling with late-stage proof and label-shaping issues. | Medium | SE005, SE003, SE006, SE007, SE008 |
| CE026 | The product chapter can verify trial design, mechanism framing, and milestone sequence, but not validated commercial manufacturing readiness. | Medium | SE016, SE018, SE008 |
| CE027 | Biosplice's public product architecture for OA consists of a single injection asset, a trial/evidence system, regulatory review, and eventual specialist administration rather than a multi-module device stack. | Medium | SE001, SE018, SE008 |
| CE028 | The oncology side of the platform uses oral administration in some studies, which shows that the underlying splicing approach is not tied to one route of delivery. | Medium | SE020, SE021 |
| CE029 | The company's public mechanism narrative starts from Wnt pathway modulation and links it to alternative pre-mRNA splicing control. | Medium | SE009, SE004 |
| CE030 | The lorecivivint evidence package appears strongest when structure, pain, and function move together, and weakest when pain endpoints miss despite other signals. | Medium | SE005, SE006, SE007 |
| CE031 | Because the product is administered by clinicians in trials, deployment risk is more about approval, reimbursement, and site readiness than about patient self-onboarding. | Medium | SE018, SE019, SE008 |
| CE032 | The 2025 ACR program and the active AML study support the view that Biosplice continues to invest in platform breadth even while the OA asset approaches review. | Medium | SE014, SE022 |
| CE033 | Public sources do not show external manufacturing partners, cold-chain requirements, or finished-product release metrics, leaving a meaningful product-risk blind spot. | Medium | SE001, SE002, SE008 |
| CE034 | The existence of multiple phase 2 and phase 3 OA trials, plus an NDA filing, supports high maturity for clinical development but not yet for commercial operations. | High | SE016, SE017, SE018, SE019, SE008 |
| CE035 | The product roadmap from public evidence is clear on past clinical milestones and current regulatory review, but unclear on launch support infrastructure and manufacturing scale-up. | Medium | SE008, SE002, SE001 |
| CE036 | The most important public trust controls are blinded randomized study design and repeated external publication rather than public operational certifications. | Medium | SE016, SE018, SE023, SE025 |
| CE037 | The strongest public differentiation claim is not software-like product complexity but a first-in-class therapeutic mechanism pursued across multiple indications. | Medium | SE009, SE002, SE022 |
| CE038 | The weakest part of the public product record is post-approval operating detail: manufacturing, quality-system specifics, pharmacovigilance process detail, and commercial support readiness remain mostly private. | Medium | SE008, SE002 |
| CE039 | Overall, Biosplice's product story is technically distinctive and clinically mature, but still operationally opaque where commercialization quality systems should become visible. | Medium | SE008, SE023, SE018, SE002 |
| CU001 | Biosplice does not yet show a public commercial patient base for lorecivivint; the most visible current "customers" are regional commercialization partners and clinical stakeholders. | High | SU001, SU002, SU003, SU004 |
| CU002 | Haisco is the named China commercialization partner for lorecivivint. | Medium | SU003, SU005, SU006 |
| CU003 | Samil is the named Korea commercialization partner for lorecivivint. | Medium | SU004, SU007, SU008 |
| CU004 | Those partner relationships provide proof of external commercial interest, but not proof of current commercial sales or renewals. | Medium | SU003, SU004, SU005 |
| CU005 | The Haisco and Samil relationships also imply that Biosplice's earliest visible customer concentration is geographic and partner-driven. | Medium | SU003, SU004 |
| CU006 | ClinicalTrials.gov study records show large multicenter site networks for the OA studies, which is evidence of broad investigator participation even before commercialization. | High | SU020, SU019, SU018 |
| CU007 | The OA-02 study enrolled 455 participants, indicating meaningful early patient participation for a private biotech program. | High | SU020, SU016 |
| CU008 | STRIDES-1 enrolled 496 participants, showing continued willingness of investigators and patients to participate in late-stage lorecivivint development. | High | SU019, SU015 |
| CU009 | STRIDES-X-ray and related long-term studies support repeat follow-up engagement, but this is still a trial-retention proxy rather than a commercial renewal metric. | Medium | SU018, SU014, SU018 |
| CU010 | The PMC post-hoc analysis shows that more participants treated with 0.07 mg lorecivivint achieved clinically meaningful pain and function responses than placebo recipients. | Medium | SU010 |
| CU011 | The placebo-versus-sham paper demonstrates that substantial patient-reported improvement can also arise within control arms, which tempers simplistic customer-satisfaction readings from OA trials. | Medium | SU013 |
| CU012 | The 2026 meta-analysis reported modest pain improvement but no consistent benefit across all functional or structural outcomes, adding further caution to any broad adoption claim. | Medium | SU011 |
| CU013 | The 2020 review article still framed lorecivivint as potentially safe and well tolerated, but emphasized that phase 3 trials would determine real commercial relevance. | Medium | SU012 |
| CU014 | Biosplice's customer story is therefore still more clinical than commercial: patient response, investigator participation, and partner option value matter more than booked accounts. | Medium | SU010, SU019, SU003, SU004 |
| CU015 | NCI-sponsored cirtuvivint work creates a different kind of stakeholder proof: institutional adoption of a study rather than product purchase. | High | SU017, SU021, SU022, SU023 |
| CU016 | First-patient-dosed announcements in the NCI-sponsored AML/MDS study are proof of operational activation, but not revenue-generating customer adoption. | Medium | SU023, SU022 |
| CU017 | No retained source provides active treated commercial patient counts for lorecivivint. | Medium | SU002, SU001 |
| CU018 | No retained source provides NRR, GRR, churn, or contract-renewal metrics. | Medium | SU003, SU004 |
| CU019 | No retained source provides public customer-satisfaction surveys outside trial outcome instruments. | Medium | SU010, SU013 |
| CU020 | The named-partner proof quality is higher than logo-only proof because both Haisco and Samil are tied to specific rights, geographies, and stated economics. | Medium | SU003, SU004, SU005, SU007 |
| CU021 | The named-patient and investigator proof quality is also stronger than generic marketing because the retained sources tie responses to registered trials and published analyses. | Medium | SU010, SU015, SU014, SU011 |
| CU022 | Even so, the chapter should not overstate trial participation as customer adoption because trial subjects are not paying commercial users. | Medium | SU020, SU019, SU010 |
| CU023 | Public partner concentration risk is high because the ex-US commercialization story rests on a small number of named counterparties. | Medium | SU003, SU004, SU005 |
| CU024 | Asset concentration risk is also high because the visible customer story is dominated by one lead OA asset. | Medium | SU001, SU002 |
| CU025 | The public adoption trajectory is milestone-based rather than account-based: phase 2 participation, phase 3 participation, partner deals, and NDA filing. | Medium | SU020, SU019, SU003, SU004, SU002 |
| CU026 | There is no public evidence of repeat purchasing, reorder rates, or contract expansion for a commercial lorecivivint business. | Medium | SU003, SU004, SU002 |
| CU027 | Trial follow-up durations and crossover designs offer only weak proxies for durability because they test engagement under protocol rather than customer willingness to repurchase. | Medium | SU018, SU013 |
| CU028 | The PubMed search result set shows a real body of external literature around lorecivivint, which supports stakeholder awareness even though it does not prove market adoption. | Medium | SU024, SU012, SU011 |
| CU029 | The ACR on Air episode provides a practitioner-attention signal, suggesting that rheumatology audiences are at least aware of the program. | Medium | SU025 |
| CU030 | Public buyer and payer proof remains thin relative to partner and patient proof; the clearest payer references still come indirectly through future access discussions rather than executed contracts. | Medium | SU002, SU004 |
| CU031 | If approved, the likely customer chain would separate partner/licensee, prescribing clinician, payer, and patient rather than collapse them into one actor. | Medium | SU003, SU004, SU015 |
| CU032 | Biosplice's strongest named-customer-style evidence is therefore not current revenue accounts but counterparties willing to license rights and institutions willing to run studies. | Medium | SU003, SU004, SU022, SU015 |
| CU033 | Current visible customer segments are partner pharma companies, clinical investigators/sites, patients in registered studies, and future payers still lacking hard public proof. | Medium | SU003, SU004, SU015, SU010 |
| CU034 | China and Korea are the named ex-US partner geographies in the retained source set. | Medium | SU003, SU004 |
| CU035 | The NCI-sponsored AML study expands stakeholder proof beyond OA and shows that external institutions will operationalize the company's programs. | Medium | SU022, SU017, SU023 |
| CU036 | Commercial treated-patient count should be recorded as null rather than zero, because the product is not commercially launched and no public count is disclosed. | Medium | SU002, SU001 |
| CU037 | Reference quality is highest where a named partner or named study is corroborated by at least one independent domain. | Medium | SU003, SU005, SU004, SU007, SU015, SU010 |
| CU038 | Overall, the customer chapter supports real stakeholder pull but not yet a diversified, measurable commercial customer base. | Medium | SU003, SU004, SU010, SU002 |
| CR001 | The core regulatory risk is that NDA submission does not guarantee approval, label breadth, or timing. | Medium | SR001, SR003 |
| CR002 | Mixed OA-10 and OA-11 all-comer results materially weaken a simple efficacy narrative. | High | SR002, SR004, SR005 |
| CR003 | OA-21's 12-week primary pain miss shows late-stage endpoint sensitivity remains a live risk even after positive structural narratives. | Medium | SR003 |
| CR004 | The meta-analysis adds independent caution by reporting only modest pain improvement and no consistent benefit across all outcomes. | Medium | SR025 |
| CR005 | Placebo-versus-sham results show that control-arm improvement can be large in knee-OA injection trials, complicating signal interpretation and future commercialization claims. | Medium | SR026 |
| CR006 | If approval is delayed or the label is narrow, the commercialization timetable and financing posture could deteriorate quickly. | Medium | SR001, SR017 |
| CR007 | ClinicalTrials.gov and NCI sources confirm the company operates within a highly regulated environment across OA and oncology programs. | Medium | SR009, SR004, SR007, SR028 |
| CR008 | The patent record confirms Biosplice owns a non-trivial body of assigned patents, but public assignment lists do not prove enforceability or freedom to operate. | Medium | SR014, SR015 |
| CR009 | No retained source surfaced active litigation or enforcement against the company, but that absence is weaker than a targeted docket search. | Medium | SR014, SR015 |
| CR010 | The missing public terms-of-use and privacy-policy pages create a small but real governance/transparency concern for external diligence. | High | SR012, SR013 |
| CR011 | A missing company-hosted NDA news permalink on the public website is another minor but visible web-governance gap. | Medium | SR031 |
| CR012 | For a biotech this web-governance gap is not thesis-breaking on its own, but it weakens confidence in outward-facing compliance hygiene. | Medium | SR012, SR013 |
| CR013 | Manufacturing, CMC, and launch-support systems remain largely opaque in public materials, which is a meaningful operational risk near commercialization. | Medium | SR023, SR001 |
| CR014 | The missing CMS coverage page and lack of public payer contracts underline that access and reimbursement proof remain unresolved. | Medium | SR011, SR001 |
| CR015 | Biosplice is highly concentrated on a single lead OA asset for near-term value realization. | Medium | SR023, SR001 |
| CR016 | Partner concentration is also high because the named ex-US commercialization story depends on a small number of counterparties broadly. | Medium | SR021, SR022, SR020 |
| CR017 | The public financial-model risk is elevated because Form D filings and press releases do not reveal current cash, monthly burn, or runway months. | High | SR016, SR017, SR001 |
| CR018 | The reported 2026 retail raise remains weakly supported and should be treated as a risk-amplifying uncertainty rather than confirmed mitigation. | Medium | SR019, SR017, SR001 |
| CR019 | The terminated SM08502 combination study is an adverse portfolio signal because it shows business reasons can halt programs even when scientific questions remain open. | Medium | SR007 |
| CR020 | Partner deals partly mitigate funding and market-entry risk by creating external validation and regional execution channels. | Medium | SR021, SR022, SR020 |
| CR021 | Partner deals also amplify dependency risk because a few counterparties can shape ex-US execution quality and economics. | Medium | SR021, SR022 |
| CR022 | The strongest operational proof today is the company's ability to run large multicenter studies and sustain external investigator participation. | High | SR006, SR004, SR005 |
| CR023 | That proof does not automatically translate into launch excellence, payer access, or post-approval pharmacovigilance readiness. | Medium | SR004, SR001 |
| CR024 | The most direct thesis-break triggers are approval delay, weak label, poor reimbursement, failure to validate cash adequacy, and partner underperformance. | Medium | SR001, SR011, SR017, SR021 |
| CR025 | Competitive and clinical setbacks in the broader OA field, cited by Fierce, suggest that late-stage failure risk in this indication is not theoretical. | Medium | SR020 |
| CR026 | The company's own forward-looking statements explicitly warn that regulatory review and commercialization outcomes remain uncertain. | Medium | SR001 |
| CR027 | A weak payer-access outcome could compress pricing, slow adoption, and reduce the value of both U.S. and ex-US partnerships. | Medium | SR011, SR021, SR022 |
| CR028 | If approval slips, the company may need more capital before meaningful product revenue arrives, increasing dilution risk. | Medium | SR001, SR017, SR018 |
| CR029 | If partner execution underperforms, geographic optionality shrinks and concentration risk becomes more punitive. | Medium | SR021, SR022 |
| CR030 | The public patent record is a supporting moat signal, but not a substitute for asset-specific legal diligence on scope, expiry, and enforceability. | Medium | SR014, SR015 |
| CR031 | The risk stack that transmits most directly into valuation is regulatory risk first, followed by financing opacity, payer access, and partner concentration. | Medium | SR001, SR017, SR011, SR021 |
| CR032 | Missing public web policies are small relative to drug-approval risk, but they are unusual enough to preserve as a diligence item. | Medium | SR012, SR013 |
| CR033 | No retained source provides a definitive public launch-readiness checklist covering manufacturing, supply, medical affairs, and pharmacovigilance. | Medium | SR001, SR023 |
| CR034 | No retained source proves active payer coverage, CMS coding, or formulary wins for lorecivivint. | Medium | SR011, SR001 |
| CR035 | The combination of a single lead OA asset and opaque cash position makes financing risk harder to separate from regulatory risk. | Medium | SR023, SR017, SR001 |
| CR036 | Because the customer story is still pre-commercial, customer concentration and reimbursement risks will not be fully observable until after approval. | Medium | SR021, SR022, SR001 |
| CR037 | The NCI-sponsored oncology collaboration is a positive institutional signal, but it does little to reduce the OA launch-risk stack. | Medium | SR028, SR029, SR001 |
| CR038 | Operational diligence should focus on CMC, supply chain, safety operations, and launch staffing rather than additional generic market-size work. | Medium | SR001, SR023 |
| CR039 | Public-data precision is lowest on cash adequacy, legal exposure beyond patent assignments, and exact payer readiness. | Medium | SR017, SR014, SR011 |
| CR040 | On balance, Biosplice faces a credible but concentrated risk stack typical of late-stage biotech, with approval and commercialization execution as the two decisive variables. | Medium | SR001, SR003, SR017, SR021 |
| CR041 | The absence of active-litigation proof should be treated as an open diligence path, not an all-clear signal. | Medium | SR014, SR015 |
| CR042 | The public risk record already justifies a high residual-severity score for approval, financing, and access risks even before full internal diligence. | Medium | SR001, SR017, SR011 |
| CV001 | Lorecivivint had an NDA on file by January 2026, but public sources reviewed for this run do not show final approval or commercial launch metrics. | High | SV001, SV002, SV003, SV027, SV018, SV021 |
| CV002 | The most widely corroborated historic equity mark is Samumed's August 2018 $438M round at a reported $12B pre-money valuation. | Medium | SV032, SV025, SV034 |
| CV003 | Biosplice publicly announced a $120M equity financing in April 2021. | High | SV004, SV025, SV034 |
| CV004 | SEC Form D filings in 2021 and 2022 corroborate that financing activity continued after the rebrand, but they do not disclose a current enterprise value. | High | SV006, SV007 |
| CV005 | Tracxn's funding page reports $778M total funding across three rounds, with the latest $120M round on April 15, 2021. | Medium | SV025 |
| CV006 | Dealroom still labels Biosplice a decacorn and reports roughly ten investors on the cap table, but explicitly describes the ownership data as estimated. | Medium | SV011 |
| CV007 | UpMarket presents a $12.44B latest price reference and an $11B platform estimate, both framed as model- or reference-based rather than a freshly priced round. | Medium | SV009 |
| CV008 | Notice provides a $4.87 per-share style private-market headline, but the retained page does not turn that into audited intrinsic value. | Medium | SV008 |
| CV009 | The public tracker stack appears to lean on stale private references and model outputs rather than a newly disclosed priced financing. | Medium | SV009, SV008, SV011, SV025 |
| CV010 | Seedtable's Biosplice and Samumed pages show that tracker summaries disagree on the number of rounds and investors, reinforcing that these pages are context, not a cap table. | Medium | SV012, SV035 |
| CV011 | Tracxn's company profile lists Biosplice at Series B stage and shows multiple active legal entities with dated employee counts, which is useful context but not a live underwriting model. | Medium | SV034 |
| CV012 | VentureRadar frames Biosplice as a privately held Wnt/RNA platform and surfaces similarity peers such as Surrozen, Skyhawk, Frequency Therapeutics, and Arrakis. | Medium | SV033 |
| CV013 | Caplight surfaces OrthoTrophix, Kolon TissueGene, and Eupraxia as similarity-based comparables rather than direct priced substitutes. | Medium | SV010 |
| CV014 | The Haisco licensing transaction was publicly described as worth up to $140M, including $20M in upfront and early development milestones. | High | SV014, SV015 |
| CV015 | The Samil transaction was publicly described as worth up to $70M in aggregate value. | High | SV016, SV017 |
| CV016 | Those regional licensing economics are meaningful validation, but on their own they do not justify an $11B-$12B equity value for the whole company. | Medium | SV014, SV015, SV016, SV017 |
| CV017 | Synapse lists lorecivivint as an NDA/BLA-stage program in the United States as of January 2026, which supports late-stage value but not approval certainty. | Medium | SV027, SV001 |
| CV018 | Synapse's organization profile indicates Biosplice still has multiple non-OA programs, so there is platform optionality beyond lorecivivint. | Medium | SV026 |
| CV019 | Synapse also shows cirtuvivint still in phase 2 and related oncology settings, which makes that program more like option value than near-term cash-flow support. | Medium | SV028 |
| CV020 | Three retained alopecia studies show Biosplice advanced SM04554 through multiple phase 2 and phase 2/3 studies, illustrating breadth but also the age and non-core nature of some legacy pipeline work. | Medium | SV029, SV030, SV031 |
| CV021 | The retained clinical evidence does not support a clean premium multiple because the public record still includes mixed late-stage OA outcomes and an adverse meta-analysis. | Medium | SV018, SV019, SV020 |
| CV022 | Public sources reviewed for this report do not disclose product revenue, realized launch pricing, gross margin, or commercial uptake for lorecivivint. | High | SV001, SV002, SV021 |
| CV023 | Public sources also do not disclose current cash on hand, monthly burn, or runway months. | High | SV006, SV007, SV025, SV011 |
| CV024 | No retained source provides a live preference stack, option-pool terms, or liquidation waterfall for Biosplice. | Medium | SV011, SV012, SV035 |
| CV025 | The July 2026 retail-raise narrative remains weakly supported and should not be used as a primary valuation anchor until primary transaction evidence appears. | Medium | SV013, SV007, SV025 |
| CV026 | Across 2018, 2021, and 2022 evidence, Biosplice clearly had repeated access to private capital. | High | SV005, SV004, SV006, SV007 |
| CV027 | That historical access to capital does not itself prove what price a new investor should pay today. | Medium | SV005, SV004, SV025, SV009 |
| CV028 | UpMarket explicitly warns that private-share transactions are illiquid, speculative, and can result in total loss of capital. | Medium | SV009 |
| CV029 | Dealroom's estimated $170M patent-portfolio figure and 70 active patent families indicate asset depth, but not directly monetizable equity value. | Medium | SV011, SV022 |
| CV030 | Patent and platform breadth help explain why Biosplice attracted large historical funding, but they do not bridge approval, access, or financing-opacity risks. | Medium | SV011, SV022, SV026 |
| CV031 | The positive thesis is that Biosplice combines a late-stage OA asset, real regional partner economics, and a historically exceptional funding record. | Medium | SV001, SV014, SV016, SV032, SV004 |
| CV032 | The anti-thesis is that the visible valuation stack is stale, tracker-driven, and unsupported by current cash-flow, cap-table, or launch-disclosure evidence. | Medium | SV009, SV008, SV011, SV007, SV020 |
| CV033 | A supportable bull case requires approval, a workable label, reimbursement traction, validated launch readiness, and investor-friendly terms. | Medium | SV001, SV002, SV009 |
| CV034 | A supportable base case is to maintain access and diligence rights while withholding a buy judgment until private metrics convert tracker context into real underwriting. | Medium | SV009, SV011, SV025 |
| CV035 | A supportable bear case is that approval slips or access disappoints, forcing additional financing against a stale private mark. | Medium | SV020, SV007, SV009, SV013 |
| CV036 | The comp evidence is too heterogeneous for a clean revenue or asset multiple because the surfaced peers span Wnt regenerative biotechs, RNA companies, and secondary-market private profiles. | Medium | SV010, SV033, SV034 |
| CV037 | Non-OA pipeline programs should be treated as upside optionality or free call options rather than core justification for today's entry price. | Medium | SV026, SV028, SV023, SV024 |
| CV038 | The 2018 $12B mark is best treated as historical ceiling context rather than current fair value. | Medium | SV032, SV025, SV009 |
| CV039 | Current public evidence does not support underwriting an $11B-$12B entry with high confidence. | Medium | SV009, SV008, SV011, SV020, SV007 |
| CV040 | The highest-value diligence asks now are a signed term sheet, current cap table, cash bridge, label scenarios, pricing and reimbursement plan, and launch-readiness package. | Medium | SV007, SV009, SV002, SV011 |
| CV041 | The recommendation that follows from the public record is research-more / track rather than buy. | Medium | SV009, SV011, SV007, SV020 |
| CV042 | Confidence should be medium-low: the financing history and stage are well evidenced, but current valuation evidence is indirect and incomplete. | Medium | SV032, SV004, SV007, SV009, SV011 |
| CV043 | If private diligence shows weak cap-table cleanliness or inadequate runway, the investment thesis should break quickly. | Medium | SV007, SV011, SV009 |
| CV044 | If private diligence shows ordinary terms, adequate runway, and launch readiness at a materially lower entry, the recommendation could improve. | Medium | SV009, SV002, SV011 |